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Key Points 
Question 
What is the clinical benefit of lowering plasma triglycerides as compared to lowering low-density 
lipoprotein cholesterol? 
Findings 
In Mendelian randomization analyses involving 654,783 participants, triglyceride-lowering variants in 
the lipoprotein lipase gene and LDL-C lowering variants in the LDL receptor gene were associated with 
similar reductions in the risk of coronary heart disease per 10 mg/dl decrease in apoB-containing 
lipoproteins (odds ratios [ORs] of 0.771 and 0.773, respectively).  
Meaning 
The clinical benefit of lowering triglycerides was similar to the clinical benefit of lowering LDL-C per unit 
change in apoB and may be related to the absolute reduction in apoB-containing lipoprotein particles. 
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ABSTRACT 
IMPORTANCE:  Triglycerides and cholesterol are both carried in plasma by apolipoprotein B (apoB)-
containing lipoprotein particles.  Whether lowering plasma triglycerides reduces the risk of 
cardiovascular events to the same extent as lowering low-density lipoprotein cholesterol (LDL-C) is 
unknown.   
OBJECTIVE:  To compare the association of triglyceride-lowering variants in the lipoprotein lipase (LPL) 
gene and LDL-C lowering variants in the LDL receptor gene (LDLR) with the risk of cardiovascular disease 
per unit change in apoB. 
DESIGN, SETTING, and PARTICIPANTS: Mendelian randomization analyses evaluating the associations of 
genetic scores composed of triglyceride-lowering variants in the LPL gene and LDL-C lowering variants in 
the LDLR gene, respectively, with the risk of cardiovascular events among participants enrolled in 63 
cohort or case-control studies conducted in North America or Europe between 1948 and 2017.  
EXPOSURES:  Differences in plasma triglycerides, LDL-C and apoB levels associated with the LPL and 
LDLR genetic scores. 
MAIN OUTCOMES AND MEASURES:  Odds ratio (OR) for coronary heart disease (CHD) - defined as 
coronary death, myocardial infarction or coronary revascularization - per 10 mg/dL decrease in apoB-
containing lipoproteins.  
RESULTS:  A total of 654,783 participants including 91,129 cases of CHD were included (mean age 62.7 
years; 51.4% women).  For each 10 mg/dL decrease in apoB-containing lipoproteins, the LPL score was 
associated with 69.9 (95%CI:68.1-71.6;p=7.1x10-1363) mg/dl lower triglycerides and 0.7 (95%CI:0.03-
1.4;p=0.039) mg/dl higher LDL-C; while the LDLR score was associated with 14.2 (95%CI:13.6-
14.8;p=1.4x10-465) mg/dl lower LDL-C and 1.9 (95%CI:0.1-3.9;p=0.036) mg/dl lower triglycerides. Despite 
these differences in associated lipid changes, the LPL and LDLR scores were associated with very similar 
reductions in the risk of CHD per 10 mg/dl decrease in apoB-containing lipoproteins (OR: 0.771, 
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95%CI:0.741-0.802,p=3.9x10-38; OR: 0.773, 95%CI:0.747-0.801,p=1.1x10-46, respectively).  In 
multivariable Mendelian randomization analyses, the associations between triglycerides and LDL-C with 
the risk of CHD became null after adjusting for changes in apoB (triglycerides OR:1.014, 95%:0.965-
1.065,p=0.189; LDL-C OR:1.010, 95%:0.967-1.055,p=0.186; apoB OR:0.761, 95%CI:0.723-
0.798,p=7.51x10-20).    
CONCLUSIONS AND RELEVANCE:   Triglyceride-lowering LPL variants and LDL-C lowering LDLR variants 
were associated with similar reductions in the risk of CHD per unit change in apoB. Therefore, the 
clinical benefit of lowering triglycerides and LDL-C may be proportional to the absolute change in apoB. 
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INTRODUCTION 
All major clinical guidelines recommend treatment to lower plasma LDL cholesterol (LDL-C) because 
numerous randomized trials have demonstrated that therapies that lower LDL-C by reducing LDL 
particles through up-regulation of the LDL receptor (LDLR) reduce the risk of cardiovascular events.1-5  By 
contrast, the guidelines do not recommend treatment to lower plasma triglycerides because 
randomized trials have not provided consistent evidence that lowering plasma triglycerides reduces the 
risk of cardiovascular events.1,2 
 
Several novel therapies that potently reduce triglycerides are currently in development.6-8  The 
development of these therapies has been motivated in part by the observation that rare loss-of-function 
mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglycerides and a 
higher risk of cardiovascular disease; while rare loss-of-function mutations in the APOC3, ANGPTL3, and 
ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglycerides and a 
corresponding lower risk of cardiovascular disease.9-13  However, whether lowering plasma triglycerides 
by targeting the LPL pathway will reduce the risk of cardiovascular events is unknown. 
 
Both triglycerides and cholesterol are carried in plasma by apolipoprotein B (apoB) containing 
lipoprotein particles.  Because all apoB-containing lipoproteins, including triglyceride-rich lipoprotein 
particles and LDL particles, have a single apoB molecule the clinical benefit of lowering triglycerides can 
be compared with the clinical benefit of lowering LDL-C by estimating their effects per unit change in 
apoB.  Therefore, the objective of this study was to use Mendelian randomization to compare the 
association of triglyceride-lowering LPL variants and LDL-C lowering LDLR variants with the risk of 
cardiovascular disease per unit change in apoB, to make inferences about the potential clinical benefit of 
lowering plasma triglycerides as compared to lowering LDL-C. 
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METHODS 
STUDY POPULATION   
The study included individual participant data from 367,641 participants enrolled in the UK Biobank 
study, individual participant data from 102,837 participants enrolled in one of 14 prospective cohort or 
case-control studies that reported data on cardiovascular outcomes in the US National Center for 
Biotechnology Information Database of Genotypes and Phenotypes program (dbGAP), and summary 
level data from 184,305 participants enrolled in one of 48 prospective cohort, case-control or cross-
sectional studies included the Coronary Artery Disease Genomewide Replication and Meta-Analysis plus 
the Coronary Artery Disease (CARDIoGRAMplusC4D) consortium.14-16  Participants of European descent 
in the UK Biobank, and all racial/ethnic groups for which cardiovascular data were reported in the 
dbGAP and CARDIoGRAMplusC4D consortium studies were included in the analysis.  In each included 
study, race/ethnicity was self-identified using a study-specific fixed-category questionnaire and was 
recorded to allow assessment of potential heterogeneity of effect estimates by ethnicity.  Contributing 
studies received ethical approval from their respective institutional review boards, and written informed 
consent was obtained from all participants.  A description of the included studies and the genotyping 
platforms used in each study is provided in eTable 1. 
  
GENETIC INSTRUMENTS 
The LPL genetic score was constructed by combining all variants within 100kb on either side of the LPL 
gene that were associated with plasma triglyceride levels at genome wide level of significance 
(P<5.0×10−8) as reported by the Global Lipids Genetics Consortium and that were in low linkage 
disequilibrium (r2<0.3) with all other variants included in the score.17,18  The LDLR genetic score was 
constructed similarly by combining all variants within 100kb on either side of the LDLR gene that were 
associated with plasma LDL-C levels at genome wide level of significance and that were in low linkage 
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disequilibrium (r2<0.3) with all other variants included in the score.  The exposure allele for each LPL 
variant was defined as the allele associated with lower plasma triglycerides, and the exposure allele for 
each LDLR variant was defined as the allele associated with lower LDL cholesterol levels.17,18 For each 
participant, an LPL genetic score was calculated by summing the number of triglyceride-lowering alleles 
that participants inherited at each variant included in the LPL score; and an LDLR score was calculated by 
summing the number of LDL cholesterol-lowering alleles that participant inherited at each variant 
included in the LDLR score.  Participants were excluded if they had missing data for one or more variants 
included in either genetic score.   
 
STUDY OUTCOMES 
The primary clinical outcome was coronary heart disease (CHD) defined as a composite of prevalent or 
the first incident occurrence of myocardial infarction (MI), coronary revascularization, or coronary 
death.  For analyses involving individual participant data, the primary clinical outcome was harmonized 
across all included studies.   For analyses involving summary level data, the definition of coronary heart 
disease (CHD) was defined by each study included in the CARDIoGRAMplusC4D consortium; which 
included CHD death, MI and coronary revascularization but in some studies also included chronic stable 
angina, or > 50% stenosis in a major epicardial coronary artery.16    
 
STUDY DESIGN AND STATISTICAL ANALYSIS 
A description of the study design, analyses performed, and data used for each analysis is provided in 
eFigure 1.  The association of each genetic score with plasma triglycerides, LDL-C and apoB was 
evaluated using linear regression, and with CHD risk using logistic regression.  All regression analyses 
were performed separately in each of the included studies adjusting for age, gender and the first five 
principal components of ancestry.  To directly compare the clinical benefit of lower triglycerides due to 
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the LPL score with lower LDL-C due to the LDLR genetic score, the associations of each score with risk of 
CHD was scaled for a common 10 mg/dl mg/dL decrease in apoB-containing lipoproteins.  For individual 
participant data, the scaled point estimates were obtained by weighting each variant included in either 
genetic score by its associated change in apoB.  For summary level data, the scaled associations were 
obtained by dividing the reported point estimate (and standard error) for an outcome by the reported 
point estimate for apoB (measured in mg/dL). The scaled summary point estimates for all variants 
included in a score were then combined in a fixed-effect inverse variance-weighted meta-analysis to 
estimate the association between that genetic score generated using summary data and the outcome 
for a 10 mg/dL change in apoB-containing lipoproteins.  The point estimates derived from the individual 
participant data and the summary data were then combined across studies in a fixed-effect inverse 
variance-weighted meta-analysis to produce an overall summary point estimate using a previously 
reported method that accounts for correlation between variants.23   
 
Effect modification between lowering triglycerides through the LPL pathway and lowering LDL-C through 
the LDL receptor pathway was assessed by comparing the associations of each genetic score with the 
risk of CHD stratified by the other genetic score. The association of combined exposure to triglyceride-
lowering LPL variants and LDL-C lowering LDLR variants with the risk of CHD was evaluated in a 2x2 
factorial Mendelian randomization analysis.19-22  For both the stratified and factorial analyses, 
associations with the risk of CHD was necessarily restricted to participants with individual data; and 
associations with changes in triglycerides, LDL-C and apoB were necessarily restricted to participants 
with individual data for whom one or more lipid measurements were available.   
 
SENSITIVITY ANALYSES 
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To compare the potential clinical benefit of pharmacologically lowering triglycerides and lowering LDL-C, 
the associations of the LDLR and LPL scores with the risk of CHD per unit change in apoB were compared 
with variants in the genes that encode the targets of current therapies that lower LDL-C through the LDL 
receptor pathway; variants in the genes that encode the targets of potential therapies that lower 
triglycerides through the LPL pathway; and variants in the apoB gene.  To compare the association of 
triglycerides and LDL-C with the risk of CHD per unit change in apoB not related to the LPL and LDLR 
genes, several additional genetic scores were constructed using up to 183 genetic variants associated 
with either triglycerides, LDL-C or both at genome-wide significance as reported by the Global Lipids 
Genetics Consortium.17,18  To further assess the independent associations of lower triglycerides, lower 
LDL-C and lower apoB on the risk of CHD, a multivariable Mendelian randomization analysis was 
performed using these 183 genetic variants combined with the LPL and LDLR variants. This analysis was 
performed using meta-regression analyses in which the dependent variable was the associated log-odds 
for the risk of CHD, and the independent variables were the reported changes in plasma triglycerides, 
LDL-C and apoB for each variant included in the analysis, weighted by the inverse of the squared 
standard error for the association of each variant with CHD; and forced to pass through the origin.  
 
All analyses were performed using Stata (version 14.2), R (version 3.2.2), or Golden Helix SNP & 
Variation Suite software (version 8.1.4). A 2-tailed P value less than .05 was considered statistically 
significant. A detailed description of the methods is provided in the Supplement.    
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RESULTS 
PARTICIPANT CHARACTERISTICS 
A total of 654,783 participants, including 91,129 cases of CHD, were included in the analysis (mean age 
62.7 years; 51.4% women).  Individual participant data was available for 470,478 participants including 
30,328 cases of CHD (Table 1).  Summary level data was available for a further 184,305 participants, 
including 60,801 cases of CHD. 
 
LPL AND LDLR GENETIC SCORES 
A total of 5 independently inherited variants were included in the LPL score (eTables 2 and 3); and 3 
independently inherited variants were included in the LDLR score (eTables 4 and 5).  Each exposure 
allele in the LPL score was associated with an inverse variance-weighted mean of 11.64 (95% CI: 10.38-
10.90; p=8.3x10-1365) mg/dl lower plasma triglycerides, 0.11 (95% CI: 0.00-0.21, p=0.039) mg/dl higher 
plasma LDL-C, and a 1.72 (95% CI: 1.30-2.14; p=5.5x10-16) mg/dl decrease in apoB-containing 
lipoproteins.  By contrast, each exposure allele in the LDLR score was associated with an inverse 
variance-weighted mean of 3.42 (95% CI: 3.27-3.57; p=2.3x10-464) mg/dl lower plasma LDL-C, 0.48 (95% 
CI: 0.03-0.93; p=0.036) mg/dl lower plasma triglycerides, and a 2.40 (95% CI: 2.02-2.79, p=3.9x10-34) 
mg/dl decrease in apoB-containing lipoproteins.   
 
ASSOCIATION OF GENETIC SCORES WITH LIPIDS AND CHD PER UNIT CHANGE IN APOB 
For each 10 mg/dl decrease in apoB-containing lipoproteins, the LPL score was associated with 69.9 
(95% CI: 68.1-71.6; p=7.1x10-1363) mg/dl lower plasma triglycerides, and 0.7 (95% CI: 0.0-1.4; p=0.039) 
mg/dl higher plasma LDL-C level (Figure 2).  By contrast, for the same 10 mg/dl decrease in apoB-
containing lipoproteins, the LDLR score was associated with 14.2 (95% CI: 13.6-14.8; p=1.4x10-465) mg/dl 
lower plasma LDL-C, and 1.9 (95% CI:  0.1-3.9; p=0.036) mg/dl lower plasma triglycerides. Despite these 
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differences in associated lipid changes, the LPL and LDLR scores were associated with very similar 
reductions in the risk of CHD per 10 mg/dl decrease in apoB-containing lipoproteins (OR: 0.771, 95% CI: 
0.741-0.802, p=3.9x10-38 for the LPL score; OR: 0.773, 95% CI: 0.747-0.801, p=1.1x10-46 for the LDLR 
score).  The associations of the LPL and LDLR scores with the risk of CHD per unit change in apoB was 
consistent between studies that contributed individual participant data and studies that contributed 
summary data (eTable 6). 
 
In stratified analyses, the associations of the LPL and LDLR scores with plasma lipids, lipoproteins and 
the risk of CHD appeared to be independent of each other (LPL score ORCHD per 10 mg/dl lower apoB: 
0.771 (95%CI: 0.714-0.832) for participants with LDLR scores below the median; 0.769 (95%CI: 0.709-
0.834) for participants with LDLR scores above the median ) (eFigure 4).  In a 2x2 factorial Mendelian 
randomization analysis, combined exposure to both the LPL and LDLR genetic scores was associated 
with linearly additive decreases in triglycerides (LPL score alone: -20.1 mg/dl [95%CI: -13.3, -28.8]; LDLR 
score alone: -3.8 mg/dl [95%CI: -15.1, +7.3]; combined exposure to both scores: -24.3 mg/dl [95%CI: -
32.4, -16.2]), LDL-C (LPL score alone: -0.1 mg/dl [95%CI: -0.5, +0.3]; LDLR score alone: -4.8 mg/dl [95%CI: 
-7.6, -2.0]; combined exposure to both scores: -4.9 mg/dl [95%CI: -7.7, -2.1]), and apoB (LPL score alone: 
-3.0 mg/dl [95%CI: -4.9, -1.2]; LDLR score alone: -3.4 mg/dl [95%CI: -5.2, -1.5]; combined exposure to 
both scores: -6.4 mg/dl [95%CI: -8.5, -4.4]); and a log-linearly additive decrease in the risk of CHD (LPL 
score alone: OR: 0.924 [95%CI: 0.889-0.960]; LDLR score alone: OR: 0.921 [95%CI: 0.885-0.958]; 
combined exposure to both scores: OR: 0.842 [95%CI: 0.811-0.874]), that was proportional to the 
absolute change in apoB but not to changes in either triglycerides or LDL-C (eFigue 5).    
 
SENSITIVITY ANALYSES 
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In additional analyses, variants in the genes that encode the targets for several potential therapies that 
lower triglycerides through the LPL pathway, and variants in the genes that encode the targets of several 
current therapies that lower LDL-C through the LDLR pathway, were also associated with very similar 
reductions in the risk of CHD per unit change in apoB as compared to the LPL and LDLR scores; and as 
compared to an APOB score composed of 8 independently inherited variants in the APOB gene (Figure 
2A).  Furthermore, the associated reduction in CHD risk for each of these variants and genetic scores 
was log-linearly proportional to their associated absolute reduction in apoB-containing lipoproteins 
(Figure 2B). 
 
Several additional genetic scores consisting of other variants associated with triglycerides or LDL-C at 
genome-wide level of significance (excluding variants in the LPL and LDLR genes), including scores 
consisting of variants associated with either triglycerides or LDL-C; triglycerides but not LDL-C; LDL-C but 
not triglycerides; both triglycerides and LDL-C with the same direction of effect; and both triglycerides 
and LDL-C with opposite directions of effect, were also associated with very similar reductions in the risk 
of CHD per 10 mg/dL decrease in apoB-containing lipoproteins (Table 2).  In multivariable Mendelian 
randomization analyses that included both triglycerides and LDL-C in the same model, the associations 
between plasma triglycerides and LDL-C with the risk of CHD were independent and genome-wide 
significant.  However, when changes in apoB were included in these analyses, the associations between 
both plasma triglycerides and LDL-C with the risk of CHD became null (triglycerides OR:1.014, 
95%:0.965-1.065,p=0.189; LDL-C OR:1.010, 95%:0.967-1.055,p=0.186; apoB OR:0.761, 95%CI:0.723-
0.798,p=7.51x10-20) (Table 3, eTable 8).   
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DISCUSSSION 
In this study, triglyceride lowering LPL variants and LDL-C lowering LDLR variants were associated with 
very similar reductions in CHD risk per unit change in apoB-containing lipoproteins. The associations 
between lower triglycerides and lower LDL-C with risk of CHD due to these variants appeared to be 
independent, additive, and proportional to the absolute change in apoB. In addition, numerous variants 
in the genes that encode the targets of potential therapies that lower triglycerides through the LPL 
pathway and current therapies that lower LDL-C through the LDLR pathway were also associated with 
very similar reductions in CHD risk per unit change in apoB.  Furthermore, multiple genetic scores 
composed of other variants associated with either triglycerides, LDL-C or both, were also associated with 
very similar reductions in the risk of CHD per unit change in apoB, even when the associated changes in 
triglycerides and LDL-C were in opposite directions.  In multivariable Mendelian randomization analyses, 
the independent and genome-wide significant associations between triglycerides and LDL-C with the risk 
of CHD became null after adjusting for changes in apoB. 
 
The results of this study suggest that the clinical benefit of lowering triglycerides is very similar to the 
clinical benefit of lowering LDL-C per unit change in apoB and is proportional to the net absolute 
reduction in apoB-containing lipoproteins.  The results of this study therefore suggest that all apoB-
containing lipoproteins particles, including triglyceride-rich VLDL particles and their metabolic remnants 
as well as LDL particles, have approximately the same effect on the risk of cardiovascular disease per 
particle.  As a result, the clinical benefit of lowering triglycerides, lowering LDL-C or lowering both may 
be proportional to the absolute change in apoB-containing lipoproteins, regardless of the observed 
changes in plasma triglycerides or LDL-C.   
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The results of this study are consistent with the current understanding of the biology of lipids and 
atherosclerosis.  Both triglycerides and cholesterol are carried in plasma by the apoB-containing 
lipoprotein particles. These particles are secreted by the liver as VLDL particles which principally contain 
triglycerides, some cholesterol and one molecule of apoB.  Lipoprotein lipase removes most of the 
triglycerides from these particles to convert the triglyceride-rich VLDL particles into triglyceride-depleted 
cholesterol-carrying LDL particles which are then removed from plasma by hepatic LDL receptors.  All 
apoB-containing lipoproteins less than 70 nm in diameter, including triglyceride-rich VLDL remnants and 
LDL particles, freely flux across the endothelial barrier where they can become retained in the artery 
wall.24  The cholesterol, and perhaps triglyceride, content of the apoB particles retained in the artery 
wall provokes an inflammatory response that leads to the initiation and progression of atherosclerotic 
plaque.25 The results of this study suggest that the effect of apoB-containing particles on the risk of 
atherosclerotic cardiovascular disease appears to be determined largely by the concentration of 
circulating apoB particles, which in turn determines the number of particles that become retained in the 
artery wall, regardless of whether those particles principally contain cholesterol or triglycerides.  Indeed, 
the present findings and interpretations based on Mendelian randomization confirm and extend the 
initial findings and interpretations in 1980 of Sniderman, Kwiterovich and their colleagues, which were 
based on cross-sectional coronary angiographic studies.26 
 
The results of this study are also consistent with prior Mendelian randomization studies demonstrating 
that triglyceride-rich apoB-containing remnant particles appear to be causally associated with the risk of 
cardiovascular disease.27,28 The results of the current study extend those findings by suggesting that 
triglyceride-rich remnant particles have approximately the same effect on the risk of cardiovascular 
disease as LDL particles.  Furthermore, the results of this study are consistent with a recent Mendelian 
randomization study that demonstrated that the causal effect of LDL particles on the risk of 
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cardiovascular disease appears to be determined by the concentration of circulating LDL particles as 
measured by apoB rather than by the mass of cholesterol carried by those particles as measured by LDL-
C.22  The results of the current study confirm and extend those findings by suggesting that the causal 
effect of all apoB-containing lipoprotein particles on the risk of cardiovascular disease appears to be 
determined by the circulating concentration of those particles rather than by the mass of cholesterol or 
triglyceride that they carry. 
 
The results of this study may also help to explain why prior randomized trials evaluating fibrates, which 
lower plasma triglycerides at least partially through the LPL pathway, have failed to consistently 
demonstrate that lowering triglycerides reduces the risk of cardiovascular events.29-33 The concentration 
of triglyceride-rich lipoproteins can be estimated by dividing plasma triglyceride concentration by 5 (on 
the milligram per decilitre scale). Therefore, if all apoB-containing particles have approximately the 
same atherogenic effect as suggested by this study, then to reduce the risk of cardiovascular events by 
20% as can be achieved by lowering LDL-C by 40-mg/dL,3,4 triglycerides must be reduced by 5-fold this 
quantity, or approximately 200 mg/dL, to achieve the same corresponding reduction in apoB-containing 
lipoproteins. However, the mean reduction in plasma triglyceride concentration in the fibrate trials was 
only 20 mg/dL to 50 mg/dL, a fraction of what would be needed to significantly reduce the risk of major 
vascular events within a short-term trial. Therefore, the failure of the fibrate trials appears to be 
explained by the modest reduction in triglycerides and therefore the modest reductions in apoB-
containing lipoproteins observed in these studies.  Future randomized trials evaluating novel therapies 
that lower plasma triglycerides should be designed based on the net absolute reductions in apoB-
containing lipoproteins that can be achieved with those therapies, rather than on the corresponding 
therapeutic changes in triglycerides or LDL-C, particularly for therapies that alter plasma concentrations 
of both triglycerides and LDL-C either in the same or competing directions.   
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LIMITATIONS 
This study has several limitations.  First, this study compared triglyceride and LDL-C lowering genetic 
variants not lipid lowering therapies.  Second, genetic variants reflect the effect of lifelong changes in 
apoB-containing lipoproteins on the risk of cardiovascular disease, which appear to be cumulative over 
time.5,34 As a result, the reductions in risk associated with lower triglycerides, LDL-C and apoB reported 
in this study are much larger than what have been reported for lipid lowering therapies in randomized 
trials.  However, having first established that the association between lifetime exposure to lower 
triglycerides and LDL-C on the risk of cardiovascular disease is approximately the same per unit change 
apoB, it is reasonable to then anticipate that short-term pharmacologic reductions in plasma 
triglycerides and LDL-C will be associated with the same reduction the risk of cardiovascular events per 
unit change in apoB.20  Third, this study specifically estimates the clinical benefit of the lipid lowering 
effect of therapies that reduce plasma triglycerides, LDL-C or both; but not the other potential 
pleiotropic effects that a therapy may have on the risk of cardiovascular disease.  Indeed, the reported 
reduction in cardiovascular events in the JELIS and REDUCE-IT Trials were far greater than what would 
have been expected from the modest observed changes in plasma lipid levels, thus suggesting that the 
observed clinical benefit of the omega-3 fatty acid eicosapentaenoic acid may be largely due to its non-
lipid related effects.35,36   
 
CONCLUSIONS 
Triglyceride-lowering LPL variants and LDL-C lowering LDLR variants were associated with very similar 
reductions in the risk of CHD per unit change in apoB, suggesting that the clinical benefit of lowering 
triglycerides and is very similar the clinical benefit of lowering LDL-C for the same change in apoB-
18 
 
containing lipoproteins. Therefore, the clinical benefit of lowering triglycerides, LDL-C or both may be 
proportional to the absolute change in apoB. 
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TABLES: 
Table 1: Baseline characteristics of included participants  
Baseline Characteristics 
No. participants 
with available data 
Participant 
Summary 
Sample Size, No. 654,783 654,783 
CHD cases, No. 654,783 91,129 
Age, mean (SD), y 654,783 62.7 (± 8.1) 
Women, No. (%) 654,783 336,462 (51.4%) 
Systolic Blood Pressure, mean (SD), mmHg 470,478 132.1 (± 18.2) 
Diastolic Blood pressure, mean (SD), mmHg 470,478 80.9 (± 9.3) 
Body mass index, mean (SD), kg/m2 470,478 27.5 (± 4.9) 
Prevalent Diabetes, No. (%) 470,478 21,642 (4.6%) 
Current smoker, No. (%) 470,478 43,284 (9.2%) 
Total cholesterol, mean (SD), mg/dl 31,221 206.6 (± 39.4) 
Low-density lipoprotein cholesterol, mean (SD), mg/dl 31,221 129.7 (± 32.1) 
High-density lipoprotein cholesterol, mean (SD), mg/dl 31,221 52.0 (± 15.4) 
Triglycerides, median (IQR), mg/dl 31,221 117.6 (84.1 – 163.3) 
Apolipoprotein B, mean (SD), mg/dl 31,221 101.4 (± 27.3) 
Non-high-density lipoprotein cholesterol  
(Total cholesterol – HDL-C), mg/dl 
31,221 154.9 (± 38.3) 
Remnant cholesterol,  
(total cholesterol – HDL-C – LDL-C), mg/dl 
31,221 23.9 (15.9 – 32.8) 
 
Table 1 Legend:   Data for age and gender were available for all 654,783 participants included in the 
primary analysis.  Data for other non-lipid baseline characteristics were available for 470,478 
participants with individual level data enrolled in the UK Biobank or one of the 14 case-control or cohort 
studies that reported cardiovascular outcomes in the database of genotypes and phenotypes program 
(dbGAP).  Data for baseline lipid measurements were available for 31,221 participants with individual 
data enrolled in one of the dbGAP studies and for whom lipid measurements were available (the UK 
Biobank has not yet released lipid measurements of enrolled participants). Non-HDL-C and remnant 
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cholesterol are calculated values.  LDL-C is low-density lipoprotein cholesterol; HDL-C is high-density 
lipoprotein cholesterol; SD is standard deviation; IQR is interquartile range. 
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Table 2: Association of additional genetic scores with triglycerides, LDL-C and risk of coronary heart 
disease per 10 mg/dl decrease in apoB-containing lipoproteins    
 
Composition of Genetic score ∆ triglycerides  
(95% CI) 
∆ LDL-C  
(95% CI) 
ORCHD  
(95% CI) 
    
51 variants associated with triglycerides at p < 
5.0x10-8; but not LDL-C (p > 0.001) 
 
-43.1 
(-44.5, -41.7) 
-2.1  
(-2.6, -1.6) 
0.762  
(0.724 - 0.803) 
59 variants associated with LDL-C at p < 5.0x10-8; 
but not triglycerides (p > 0.001) 
 
-2.1  
(-3.0, -1.1) 
-15.5 
(-15.8, -15.1) 
0.774  
(0.748 - 0.800) 
173 variants associated with either triglycerides 
or LDL-C at p < 5.0x10-8 
 
-21.6  
(-22.1, -21.1) 
-11.8  
(-12.0, -11.6) 
0.770  
(0.757 - 0.783) 
91 variants associated with triglycerides at p < 
5.0x10-8 
 
-35.3  
(-35.9, -34.6) 
-9.3  
(-9.6, -9.1) 
0.776  
(0.758 - 0.795) 
 
100 variants associated with LDL-C at p < 5.0x10-8 
 
-17.5  
(-18.0, -17.0) 
-13.5 
(-13.7, -13.3) 
0.776  
(0.762 - 0.791) 
 
23 variants associated with triglycerides and LDL-
C, both at p < 5.0x10-8; in same direction of effect 
 
-32.3  
(-33.0, -31.5) 
-12.0  
(-12.3, -11.7) 
0.793  
(0.771, 0.815) 
10 variants associated with triglycerides and LDL-
C, both at p < 5.0x10-8; with opposite directions 
of effect 
 
+17.2 
(+16.0, +18.4) 
-22.5  
(-23.0, -22.1) 
0.798  
(0.767 - 0.830) 
9 variants associated with triglycerides and LDL-
C, both at p < 5.0x10-8; with opposite directions 
of effect (excluding APOE variant rs7412) 
 
+26.0  
(+23.7, +28.3) 
-20.3 
(-21.2, -19.4) 
0.770  
(0.711 - 0.833) 
 
Table 2 Legend:  To compare the association of triglycerides and LDL-C with the risk of CHD for the same decrease 
in the concentration of apoB-containing lipoproteins not related to the LPL and LDLR genes, several additional 
genetic scores were constructed using up to 173 genetic variants associated with either triglycerides, LDL-C or both 
at genome-wide significance as reported by the Global Lipids Genetics Consortium (GLGC).  The data presented are 
for the associations of each genetic score with changes in triglycerides and LDL-C per 10 mg/dl decrease in apoB in 
up to 305,699 participants in GLGC; and with the risk of CHD per 10 mg/dl decrease in apoB in all 654,783 
participants included in this study.  For example, for each 10 mg/dL decrease in plasma apoB concentration 
associated with a genetic score consisting of 51 variants associated with triglycerides but not LDL-C at genome-
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wide level of significance, there was a corresponding 41.3 mg/dl decrease in triglycerides, 2.1 mg/dl decrease in 
LDL-C and a lower risk of CHD (OR: 0.76, 95%CI: 0.72-0.80).  By contrast, for the same 10 mg/dl decrease in plasma 
apoB concentration associated with a genetic score consisting of 59 variants associated with LDL-C but not 
triglycerides at genome-wide level of significance, there was a corresponding 15.5 mg/dl decrease in LDL-C, 2.1 
mg/dl decrease in triglycerides and a similar lower risk of CHD (OR: 0.77, 95%CI: 0.75-0.80). Furthermore, for the 
same 10 mg/dl decrease in plasma apoB concentration associated with a genetic score consisting of 173 variants 
associated with either triglycerides or LDL-C at genome-wide level of significance, there was a corresponding 21.6 
mg/dl decrease in triglycerides, an 11.8 mg/dl decrease in LDL-C, and a similar lower risk of CHD (OR: 0.77, 95%CI: 
0.76-0.78). Despite being associated with different changes in lipids, all genetic scores were associated with similar 
reductions in the risk of CHD for the same 10 mg/dl decrease in plasma apoB concentration.  Boxes represent 
effect size estimates and lines represent 95% confidence intervals.  The unadjusted associations with triglycerides, 
LDL-C, apoB and coronary heart disease for each variant included in the genetic scores are provided in eTable 7.   
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Table 3:  Multivariable Mendelian randomization analysis of the association between plasma 
triglycerides, LDL-C and apoB with the risk of coronary heart disease 
 
Analysis variables ORCHD (95% CI) p value 
    
Association of 10 mg/dl lower apoB with risk of 
CHD 
apoB 0.770 (0.760 - 0.781)  1.42E-170 
    
Association of 10 mg/dl lower LDL-C with risk of 
CHD 
LDL-C 0.846 (0.833 - 0.858)  8.16E-77 
    
Association of 50 mg/dl lower triglycerides with 
risk of CHD 
Triglycerides 0.815 (0.785 - 0.846)  1.37E-18 
    
Association of 10 mg/dl lower LDL-C and 50 
mg/dl lower triglycerides with risk of CHD 
included in same model 
LDL-C 0.862 (0.849 - 0.875)  6.92E-65 
Triglycerides 0.876 (0.850 - 0.902)  1.36E-14 
    
Association of 10 mg/dl lower LDL-C, 50 mg/dl 
lower triglycerides and 10 mg/dl lower apoB 
with risk of CHD included in same model 
apoB 0.761 (0.723 - 0.798)  7.51E-20 
LDL-C 1.010 (0.967 - 1.055)  0.186 
Triglycerides 1.014 (0.965 - 1.065)  0.189 
    
 
 
Table 3 Legend:  Data presented are derived from a multivariable meta-regression analysis of 191 genetic variants, 
including the 5 variants included in the LPL score, 3 variants included in the LDLR score, and 183 variants 
associated with either triglycerides, LDL-C or both at genome-wide significance as reported by the Global Lipids 
Genetics Consortium.  Effect sizes for the associated risk of coronary heart disease are reported per 10 mg/dl 
decrease in apoB; per 10 mg/dl decrease in LDL-C, or per 50 mg/dl decrease in triglycerides (because dividing 
triglyceride concentration by 5 estimates the cholesterol content carried by triglyceride-rich apoB-containing 
lipoproteins as estimated by the Friedewald formula).  In these analyses, the dependent variable was the effect 
estimate for risk of coronary heart disease in all 654,783 participants included in the study for each variant; and 
the independent variables were the effect estimates for the associated changes in plasma triglycerides, LDL-C and 
apoB, measured in up to 305,699 participants in Global Lipids Genetics Consortium for each variant. The analysis 
was weighted by the inverse squared standard error of the associated risk of CHD for each variant; and forced to 
pass through the origin.  For example, in multivariable Mendelian randomization analyses involving these 191 
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genetic variants, both triglycerides (OR: 0.876 per 50 mg/dl lower triglycerides) and LDL-C (OR: 0.862 per 10 mg/dl 
lower LDL-C) were independently associated with a lower risk of CHD at genome-wide level of significance.  By 
contrast, when apoB was included in the multivariable Mendelian randomization analyses, the associations with 
CHD for both triglycerides (OR: 1.014 per 50 mg/dl lower triglycerides) and LDL-C (OR: 1.010 per 10 mg/dl lower 
LDL-C) became null, but the association with apoB remained unchanged (OR: 0.761 per 10 mg/dl lower apoB).  The 
unadjusted associations with triglycerides, LDL-C, apoB and coronary heart disease for each variant included in the 
analysis are provided in eTable 7.  Additional multivariable meta-regression analyses for various combinations of 
these variants is provided in eTable 8.  
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FIGURES: 
Figure 1: Associations between the LPL and LDLR genetic scores with triglycerides, LDL-C and risk of 
coronary heart disease per 10 mg/dl decrease in apoB-containing lipoproteins  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 legend:  Triglycerides are carried in plasma by apoB-containing triglyceride-rich lipoproteins 
while cholesterol is carried predominantly by apoB-containing low-density lipoproteins. Changes in 
plasma triglycerides and LDL-C concentration are thus markers of the corresponding changes in the 
concentration of the apoB-containing lipoproteins that transport these lipids.  Variants in the LPL gene 
that increase LPL activity are associated with lower triglycerides and a corresponding lower apoB 
concentration, while variants in the LDLR gene that increase activity of the LDL receptor are associated 
with lower LDL-C and a corresponding lower apoB.  The Figure shows that for each 10 mg/dL decrease in 
plasma apoB concentration associated with variants in the LPL score, there is a corresponding 69.9 
mg/dl decrease in triglycerides, no change in LDL-C and a lower risk of CHD (OR: 0.77, 95%CI: 0.74-0.80).  
By contrast, for the same 10 mg/dl decrease in plasma apoB concentration associated with variants in 
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the LDLR score, there is a corresponding 14.1 mg/dl decrease in LDL-C, no change in triglycerides, and a 
similar lower risk of CHD (OR: 0.77, 95%CI: 0.75-0.80).  Therefore, despite being associated with changes 
in different lipids, the LPL and LDLR scores were associated with similar reductions in the risk of CHD for 
the same decrease in plasma apoB concentration. The data presented are for the associations of the LPL 
and LDLR genetic scores with risk of CHD per 10 mg/dl decrease in apoB-containing lipoproteins in all 
654,783 participants included in the study.  The associations of either score with changes in triglycerides 
and LDL-C per 10 mg/dl decrease in apoB-containing lipoproteins are from up to 305,699 participants 
enrolled in the Global Lipid Genetics Consortium.  Boxes represent effect size estimates and lines 
represent 95% confidence intervals. 
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Figure 2: Associations between variants in the genes that encode the targets of lipid lowering therapies 
with triglycerides, LDL-C and risk of coronary heart disease  
 
A.  Association of genetic variants and genetics scores with triglycerides, LDL-C and risk of coronary 
heart disease per 10 mg/dl decrease in apoB-containing lipoproteins 
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B.  Log-linear association between absolute changes in apoB and reduction in risk of CHD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 legend:  The Figure shows the associations with triglycerides, LDL-C and risk of CHD for the 
same 10 mg/dl decrease in apoB-containing lipoprotein concentration for variants in the LPL and LDLR 
scores as compared to variants in the genes that encode the targets of current therapies that decrease 
LDL-C through the LDL receptor pathway; variants in the genes that encode the targets of potential 
therapies that lower triglycerides through the LPL pathway; and variants in the APOB gene.  For 
example, each 10 mg/dL decrease in plasma apoB concentration associated with the partial loss-of-
function rs11591147 variant in the PCSK9 gene was associated with a corresponding 18.0 mg/dl 
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decrease in LDL-C, no change in triglycerides and a lower risk of CHD (OR: 0.77, 95%CI: 0.72-0.83).  By 
contrast, for the same 10 mg/dL decrease in plasma apoB concentration associated with the functional 
rs116843064 variant in the ANGPTL4 gene, there was a corresponding 69.4 mg/dl decrease in 
triglycerides, no change in LDL-C and a similar lower risk of CHD (OR: 0.73, 95%CI: 0.61-0.86). 
Furthermore, for the same 10 mg/dL decrease in plasma apoB concentration associated with variants in 
the APOB gene score, there was a corresponding 9.7 mg/dl decrease in triglycerides, 15.6 mg/dl 
decrease in LDL-C and a similar lower risk of CHD (OR: 0.78, 95%CI: 0.74-0.82).  Despite a range of 
associated changes in triglycerides, LDL-C or both, all genetic variants and genetic scores were 
associated with similar reductions in the risk of CHD for the same 10 mg/dL decrease in plasma apoB 
concentration.  In Panel A, the APOB score is composed of the 8 independently inherited variants in the 
APOB gene listed in the Figure.  Boxes represent effect size estimates and lines represent 95% 
confidence intervals.  In panel B, the associations of each genetic variant with apoB concentration is 
plotted against its unadjusted association with CHD, expressed as a proportional reduction in risk 
(calculated as [1-ORCHD]*100).  Variants in the genes that encode the targets of therapies that lower 
triglycerides through the LPL pathway are marked with blue labels, and variants in the genes that 
encode the targets of therapies that lower LDL-C through up-regulation of the LDL receptor are marked 
by red labels.  Circles represent the associated absolute change in apoB and corresponding proportional 
risk reduction for each variant. The horizontal lines through each circle represents ± 1 standard errors 
for the associated absolute change in apoB for each variant; and the vertical line through each circle 
represents ± 1 standard errors for the associated proportional risk reduction.  In both panels, 
associations with CHD per 10 mg/dl lower apoB were measured in all 654,783 participants included in 
the study; and in Panel A associations with changes in triglycerides and LDL-C per 10 mg/dl lower apoB 
were measured in up to 305,699 participants from the Global Lipid Genetics Consortium.   
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eMethods: 
 
I. Constructing the genetic scores 
All approximately independently inherited variants in the LPL gene that are conditionally independently 
associated with plasma triglyceride levels at genome-wide level of statistical significance (p < 5x10-8) 
were combined to create an LPL genetic score, and all approximately independently inherited variants in 
the LDLR gene that are conditionally independently associated with plasma LDL-C levels at genome-wide 
level of statistical significance were combined to create to create an LDLR genetic score.   These genetic 
scores are instruments of randomization that reflect the combined effect of the variants included in the 
respective score on plasma lipid and lipoprotein levels.   As a result, each score has a much larger effect 
on plasma lipid and lipoprotein levels than any individual variant included in the respective score.   
 
To select variants for inclusion in the LPL genetic score, the following protocol was used.  First, the 
association of each variant within a 100 KB window of the LPL gene was tested in a linear regression 
model where the dependent variable was triglycerides (the major lipid effect of lipoprotein lipase) and 
the independent variables were age, sex, study sample, and 5 principal components of ancestry to select 
the variant that was most strongly associated with plasma triglyceride levels in up to 54,837 participants 
enrolled in one of the dbGAP studies who were free of cardiovascular disease at baseline and for whom 
one or more measurements of plasma lipids and lipoproteins was available.  Next, we iteratively tested 
the association of each remaining variant in the same linear model where the dependent variable was 
triglyceride level and the independent variables were age, sex, study sample, 5 principal components of 
ancestry, plus all variants selected in a previous step of the algorithm. The variant that was associated 
with triglycerides in this conditional analysis with the lowest p-value below a threshold of 5 × 10-8 was 
added to the set of selected variants. Once a variant was included in the analysis, all other variants that 
were correlated with the selected variant at r2 > 0.3 were removed from the set of candidate variants.1,2 
We then iteratively repeated this process until all variants were either selected, removed due to linkage 
disequilibrium with a selected variant, or were not strongly associated (p < 5 × 10-8) with plasma 
triglycerides in the conditional analysis.  To select variants for inclusion in the LDLR genetic score, we 
used the same protocol except that the dependent variable was plasma LDL-C level (the major lipid 
effect of the LDL receptor) in all regression models.  This approach selected the variants in the LPL gene 
most strongly associated with triglycerides, and the variants in the LDLR gene most strongly associated 
with LDL-C.   
40 
 
 
We defined the exposure allele for each variant included in the LPL score as the allele associated with 
lower plasma triglyceride levels; and the exposure allele for each variant included in the LDLR score as 
the allele associated with lower plasma LDL-C levels as reported by the Global Lipid Genetics Consortium 
(GLGC).3,4    
 
Both triglycerides and cholesterol are carried in plasma by apoB-containing lipoproteins, which can 
become retained in the artery wall leading to the initiation and progression of atherosclerotic plaque.  
Furthermore, all apolipoprotein B containing lipoproteins synthesized by the liver (including triglyceride-
rich VLDL particles, VLDL remnant particles, and LDL particles) contain a single apoB-100 molecule the 
association of the LPL and LDLR genetic scores on lipids, lipoprotein levels and the risk of CHD can be 
compared directly per apoB-containing lipoprotein particle by comparing the associations of these 
genetic scores per unit change in plasma apoB levels.  Thus, to directly compare the effect of the LPL and 
LDLR scores, each exposure allele included in either genetic score was weighted by its effect on apoB.  
To measure the association of each variant included in the LPL score on apoB levels conditional on the 
presence of all other variants included in the LPL score, the association of each variant with apoB was 
measured in a linear regression model where the dependent variable was plasma apoB level and the 
independent variables were age, sex, study sample, the first 5 principal components of ancestry, and all 
variants included in the LPL score selected using the algorithm described above.  Similarly, to measure 
the association of each variant included in the LDLR score on apoB levels conditional on the presence of 
all other variants included in the LDLR score, the association of each variant with apoB was measured in 
a linear regression model where the dependent variable was plasma apoB level and the independent 
variables were age, sex, study sample, the first 5 principal components of ancestry, and all variants 
included in the LDLR score selected using the algorithm described above.  The conditional apoB analyses 
were performed in an independent external sample including up to 63,890 participants with available 
measurements of plasma apoB levels from the MAGNETIC NMR GWAS consortium and INTERVAL 
Bioresource studies.5,6 All studies used the same NMR platform to measure the plasma concentration of 
apoB using the same protocol.    
 
To calculate the LPL genetic score for each participant weighted by apoB, the number of exposure alleles 
that a participant inherited at each variant included in the LPL score was multiplied by the conditional 
effect of that variant on plasma apoB concentration measured in mg/dL.  These values were then 
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summed to create a weighted LPL genetic score for each participant.   Similarly, the LDLR genetic score 
for each participant weighted by apoB was calculated by multiplying the number of exposure alleles that 
a participant inherited at each variant included in the LDLR score by the conditional effect of that variant 
on plasma apoB concentration measured in mg/dL, and then summed.   
 
II.  Allocation into exposure groups for stratified and 2x2 factorial Mendelian randomization analysis 
Because all variants included in either genetic score are inherited approximately randomly at the time of 
conception in a process sometimes referred to as Mendelian randomization,7 and because each variant 
is inherited approximately independently of the other polymorphisms included in the score by virtue of 
low linkage disequilibrium as defined by the construction of the score, the number of exposure alleles 
that a person inherits in either score should also be random.   
 
To perform the stratified analyses, each genetic score was first dichotomized as having a value above or 
below the median score for participants in the population under study.   Because the number of 
exposure alleles that a person inherits in either score should be random, dichotomizing the genetic 
score as above and below the median should therefore randomly allocate participants under study into 
two approximately equal sized groups.  The association between each score and changes in plasma 
triglyceride, plasma LDL-C levels, and the risk of CHD was then measured separately among participants 
with scores less than or equal to the median and greater than the median value for the other score., and 
effect estimates were compared using a z statistic to assess for heterogeneity of effect estimates. 
 
To conduct the 2x2 factorial analyses, study participants were first randomly allocated into two groups 
based on whether their LDLR genetic score was above or below the median value.  Participants in either 
of these two groups were then randomly allocated into two further groups based on whether their LPL 
genetic score was above or below the median value.  Because all variants included in either score are 
inherited approximately randomly and approximately independently of each other due to low linkage 
disequilibrium; and because LPL and LDLR variants are located on different chromosomes and therefore 
inherited independently of the other, this process should randomly allocate participants into 4 
approximately equal-sized groups: the reference group with both scores equal to or below the median, a 
group with LPL scores above the median but LDLR scores equal to or below the median (i.e. a group with 
lower TG but not lower LDL-C compared to the reference group), a group with LDLR scores above the 
median but LPL scores equal to or below the median (i.e. a group with lower LDL-C but not lower TG 
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compared to the reference group), and a group with both scores above the median (i.e. a group with 
lower LDL-C but not lower TG compared to the reference group).8,9      
 
The success of the naturally random allocation scheme was assessed by comparing baseline 
characteristics among persons in each group being compared.  Continuous variables were compared 
using a t-test, dichotomous (and ordinal) variables were compared using a chi-square test, and non-
normally distributed variables were compared using non-parametric rank tests or empirical resampling.   
 
III.  Harmonized definition of cardiovascular outcome events 
The primary outcome for the study was CHD, defined as a composite of the first occurrence of non-fatal 
MI, coronary revascularization or coronary death.  Both prevalent and incident cases of MI were 
included in the primary composite to meet the definition of “first occurrence” (understanding that all 
coronary deaths during follow-up were necessarily incident events) in the cohort studies.  Therefore, the 
primary cardiovascular outcome is a composite of prevalent MI or prevalent coronary revascularization; 
or the first occurrence of incident MI, incident coronary revascularization or coronary death.   
 
For participants enrolled in the dbGAP studies, the definition of all cardiovascular-related outcome was 
first harmonized as previously described.10-18 Individual level data was then coded for each study 
participant as necessary to satisfy the harmonized variable definitions to the extent possible, as 
described below.   
 
In general, and where possible, only the outcomes of coronary heart disease death (as adjudicated by 
the individual studies); “definite” myocardial infarction (excluding “silent MI”, “possible MI”, “probable 
MI”, “ECG-detected prior MI” and “resuscitated cardiac arrest”); and coronary revascularization (defined 
as “angioplasty”, “percutaneous coronary intervention” or “coronary artery bypass grafting”) were 
included.  New reconciled study outcome variables were created in each data set using the definitions 
described above.   
 
We did not recode the “case” definition for the case-control studies.  In the six (6) Myocardial Infarction 
Genetics (MIGEN) Consortium case-control studies, all “cases” were MI.18   Therefore, because MI is a 
component of the primary outcome, these “cases” were included in the primary composite outcome.    
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In the Wellcome Trust Case-Control Consortium (WTCCC) study, “cases” had a history of either 
myocardial infarction or coronary revascularization before the age of 66 years, and a family history of 
coronary artery disease.19   Of the 1,926 WTCCC “cases”, 1,377 had MI (71.5%) and the remaining 549 
had coronary revascularization (202 PCI; 347 CABG) as the case ascertainment event.  Therefore all 
“cases” in the WTCCC met the criteria for a primary composite outcome event and were included in the 
analyses.   
 
In the UK Biobank, data for each of components of the primary composite outcome was available for all 
participants enrolled in the study.19 These outcomes included nonfatal MI [UK Biobank’s algorithmically 
defined myocardial infarction (ICD9: 410.X, 411.0.X, 412.X, 429.79; ICD10: I21.X, I22.X, I23.X, I24.1, I25.2; 
self-report 20002: 1075)];  PTCA or CABG (self-report 20004: 1070, 1095, 1523; Procedures (OPCS): 
K50.1, K40.X, K41.X, K42.X, K43.X, K44.X); and CHD death (Death  40001, 40002: I21.X, I22.X, I23.X, I24.X, 
I25.1, I25.2, I25.3, I25.5, I25.6, I25.6, I25.8, I25.9). 
 
The definition of CHD in studies that provided summary level data was defined by the individual studies 
included in the CARDIoGRAMplusC4D consortium (www.CARDIOGRAMPLUSC4D.org).20   
Case status was defined in these studies by an inclusive CHD diagnosis (e.g. MI, acute coronary 
syndrome, chronic stable angina, PCI or coronary stenosis >50%).  Approximately 70% of total number of 
CHD cases in the CARDIoGRAMplusC4D consortium studies were defined by a reported history of MI. 
 
IV. Analytic methods 
In studies with individual participant data, the association between each weighted genetic score and 
plasma lipid levels was evaluated using linear regression, and the association with CHD was evaluated 
using logistic regression (for combined prevalent and incident outcomes) or proportional hazards 
models (for incident events).  All analyses were adjusted for age, gender and the first five principal 
components of ancestry.   
 
In the main analysis, the associations for each score were adjusted for a standardized decrement of 10 
mg/dl lower plasma apoB concentration.  In the stratified analyses, the associations for either genetic 
score was calculated separately among participants with values of the other score equal to or below the 
median value for that score; and among participants with values of the other score above the median.  
In the 2x2 factorial analysis, the group with both the LPL and LDLR scores below the median was used as 
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the reference group.  The associations with changes in lipid levels and the risk of CHD for each group 
was compared to the reference group.   
 
To calculate association of the LPL and LDLR genetic scores on plasma lipid levels scaled for a given 
change in apoB-containing lipoproteins in studies with summary level data, the reported association was 
looked-up between each variant included in the LPL and LDLR score, respectively, with plasma 
triglycerides and LDL-C in up to 316,391 participants as reported by the Global Lipids Genetic 
Consortium (GLGC).2,3 The reported lipid effect size (and the corresponding standard error) was then 
adjusted by the conditional effect of that variant on apoB (measured in mg/dl) using the usual ratio of 
effect estimates method (i.e. dividing the effect of each variant on plasma triglycerides and LDL-C by the 
effect of that allele on apoB).  The adjusted effect estimates for each LPL variant was then combined in a 
fixed-effect inverse-variance weighted meta-analysis to measure the association between the LPL 
genetic score and plasma lipid levels per unit lower apoB.   Similarly, the adjusted effect estimates for 
each LDLR variant was combined in a fixed-effect inverse-variance weighted meta-analysis to measure 
the association between the LDLR genetic score and plasma lipid levels per unit lower apoB.    
 
To calculate association of the LPL and LDLR genetic scores on the risk of CHD scaled for a given change 
in apoB-containing lipoproteins in studies with summary level data, the association was looked-up 
between each variant included in the LPL and LDLR score, respectively, with the risk of CHD as reported 
by the CARDIoGRAMplusC4D consortium (www.CARDIOGRAMPLUSC4D.org).20  The reported CHD effect 
sizes in natural log units (and the corresponding standard error) were then adjusted by the effect of 
each variant on apoB (measured in mg/dl) ) using the usual ratio of effect estimates method (i.e. dividing 
the effect of each variant on the risk of CHD in natural log units by the effect of that allele on apoB).  The 
adjusted effect estimates for the LPL variants were then combined in a fixed-effect inverse-variance 
weighted meta-analysis to measure the association between the LPL genetic score and the risk of CHD 
per unit lower apoB; and the adjusted effect estimates for the LDLR variants were combined in a fixed-
effects inverse-variance weighted meta-analysis to measure the association between the LDLR genetic 
score and the risk of CHD per unit lower apoB.     
 
All analyses were conducted in separately in each study using individual participant data (or each 
consortium using summary level data) and then combined across all studies to produce overall summary 
estimates of effect using a generalized linear regression model that takes into account partial correlation 
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due to low linkage disequilibrium between variants included in either score.21  If variants were 
uncorrelated, this method would be equivalent to combining the variant-specific causal estimates in an 
inverse-variance weighted meta-analysis (or combining the variants into a single genetic score variable 
and calculating the Mendelian randomization ratio estimate using this score). 
 
To combine study specific effect estimates across studies, a matrix of genetic correlations between 
variants included in each score, respectively, was estimated in participants not having a previous CHD 
event at baseline only.  The regression model was: 
 
𝛽𝑌 =  𝜃 𝛽𝑋 + 𝜀, 𝜀 ~ 𝑁(0, Ω) 
 
where 𝜃 is the Mendelian randomization causal estimate, 𝛽𝑋 is a vector of the genetic associations 
(beta-coefficients) with the risk factor, 𝛽𝑌 is a vector of the genetic associations with the outcome, and 
the weighting matrix Ω has terms Ω𝑗1𝑗2 = 𝜎𝑌𝑗1𝜎𝑌𝑗2ρ𝑗1𝑗2, where 𝜎𝑌𝑗 is the standard error of the genetic 
association with the outcome for the jth variant, and ρ𝑗1𝑗2  is the correlation between the j1th and j2th 
variants. The causal estimate from this weighted generalized linear regression is 
(𝛽𝑋
𝑇Ω−1𝛽𝑋)
−1𝛽𝑋
𝑇Ω−1𝛽𝑌, and the standard error is 𝜎√(𝛽𝑋
𝑇Ω−1𝛽𝑋)−1, where 
T is a matrix transpose, 
and 𝜎 is the maximum of the residual standard error from the regression model and 1. This is equivalent 
to assuming a multiplicative random-effects model on the variant-specific causal effect estimates. By 
fixing 𝜎 to be no lower than 1, we ensure that the random-effects analysis is no more precise than a 
fixed-effect analysis would be.  This method has been described previously and was implemented using 
the Mendelian Randomization package in R (available for download at https://cran.r-
project.org/web/packages/MendelianRandomization/).  When run as a fixed-effect analysis, it is 
equivalent to the commonly-used two-stage least squares method that requires individual-level data. 
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recruited in 2006-2010 from several centers across the United Kingdom.  This research has been 
conducted using the UK Biobank Resource under Application Number 11193.  
http://www.ukbiobank.ac.uk/ 
 
ARIC Atherosclerosis Risk in Communities Study (ARIC) 11 
DbGaP dataset reference: The datasets used for the analyses described in this manuscript were obtained 
from dbGaP at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap through dbGaP Study Accession: 
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collaboration with ARIC investigators and does not necessarily reflect the opinions or views of ARIC, or 
the NHLBI. 
 
Candidate Gene Association Resource (CARe) - Support for the genotyping through the CARe Study was 
provided by NHLBI Contract N01-HC-65226. 
GENEVA (Gene-Environment Association Studies) - Support for the genotyping through the GENEVA 
Study was provided by the NIH GEI U01HG004438, U01HG04424, and HHSN268200782096C 
 
Cardiovascular Health Study (CHS) 12 
DbGaP dataset reference: The datasets used for the analyses described in this manuscript were obtained 
from dbGaP at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap through dbGaP Study Accession: 
phs000287.v4.p1 
 
The research reported in this article was supported by contract numbers N01-HC- 
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HL080295 from the National Heart, Lung, and Blood Institute and R01 AG-023629 from the National 
Institute on Aging, with additional contribution from the National Institute of Neurological Disorders and 
Stroke. A full list of principal CHS investigators and institutions can be found at http://www.chs-
nhlbi.org/pi.htm. This manuscript was not prepared in collaboration with CHS investigators and does not 
necessarily reflect the opinions or views of CHS, or the NHLBI. 
 
CHS Candidate gene Association Resource (CARe): Support for the genotyping through the CARe Study 
was provided by NHLBI Contract N01-HC-65226. 
 
Support for the Cardiovascular Health Study Whole Genome Study was provided by NHLBI grant 
HL087652. Additional support for infrastructure was provided by HL105756 and additional genotyping 
among the African-American cohort was supported in part by HL085251.  
DNA handling and genotyping at Cedars-Sinai Medical Center was supported in part by National Center 
for Research Resources grant UL1RR033176, now at the National Center for Advancing Translational 
Technologies CTSI grant UL1TR000124; in addition to the National Institute of Diabetes and Digestive 
and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research 
Center. 
 
The Framingham Heart Study (FHS) 13,14 
DbGaP dataset reference: The datasets used for the analyses described in this manuscript were obtained 
from dbGaP at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap through dbGaP Study Accession: 
phs000007.v23.p8 
 
The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood 
Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195). This manuscript 
was not prepared in collaboration with investigators of the Framingham Heart Study and does not 
necessarily reflect the opinions or views of the Framingham Heart Study, Boston University, or NHLBI. 
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FHS SNP Health Association Resource (SHARe): Funding for SHARe  Affymetrix genotyping was provided 
by NHLBI Contract N02-HL-64278. SHARe Illumina genotyping was provided under an agreement 
between Illumina and Boston University. 
 
Candidate gene Association Resource (CARe): Funding for CARe genotyping was provided by NHLBI 
Contract N01-HC-65226. 
 
Multi-Ethnic Study of Atherosclerosis (MESA) 15 
DbGaP dataset reference: The datasets used for the analyses described in this manuscript were obtained 
from dbGaP at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap through dbGaP Study Accession: 
phs000209.v12.p3 
 
MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and 
Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by 
contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, 
N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169 and CTSA UL1-RR-024156. 
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Human SNP Array 6.0. 
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this manuscript were obtained through dbGaP (accession numbers). Funding for CARe genotyping was 
provided by NHLBI Contract N01-HC-65226. 
 
Coronary Artery Risk Development in Young Adults (CARDIA) 16 
DbGaP dataset reference: The datasets used for the analyses described in this manuscript were obtained 
from dbGaP at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap through dbGaP Study Accession: 
phs000285.v3.p2 
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The research reported in this article was supported by contract numbers HHSN268201100006C, 
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, 
HHSN268201100011C, and HHSN268201100012C; all from the National Heart, Lung, and Blood Institute; 
National Institutes of Health; Bethesda, MD, USA.  A full list of principal ARIC investigators and 
institutions can be found at http://www.cardia.dopm.uab.edu/.  This manuscript was not prepared in 
collaboration with CARDIA investigators and does not necessarily reflect the opinions or views of 
CARDIA, or the NHLBI. 
 
Candidate Gene Association Resource (CARe) - Support for the genotyping through the CARe Study was 
provided by NHLBI Contract N01-HC-65226. 
GENEVA (Gene-Environment Association Studies) - Support for the genotyping through the GENEVA 
Study was provided by the NIH GEI U01HG004438, U01HG04424, and HHSN268200782096C 
 
Women's Health Initiative (WHI) 17 
DbGaP dataset reference: The datasets used for the analyses described in this manuscript were obtained 
from dbGaP at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap through dbGaP Study Accession: 
phs000200.v9.p3 
 
The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of 
Health, U.S. Department of Health and Human Services through contracts N01WH22110, 24152, 32100-
2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221. This 
manuscript was not prepared in collaboration with investigators of the WHI, has not been reviewed 
and/or approved by the Women’s Health Initiative (WHI), and does not necessarily reflect the opinions 
of the WHI investigators or the NHLBI. 
 
PAGE: WHI PAGE is funded through the NHGRI Population Architecture Using Genomics and 
Epidemiology (PAGE) network (Grant Number U01 HG004790). Assistance with phenotype 
harmonization, SNP selection, data cleaning, meta-analyses, data management and dissemination, and 
general study coordination, was provided by the PAGE Coordinating Center (U01HG004801-01). 
 
GARNET: Funding support for WHI GARNET was provided through the NHGRI Genomics and Randomized 
Trials Network (GARNET) (Grant Number U01 HG005152). Assistance with phenotype harmonization and 
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genotype cleaning, as well as with general study coordination, was provided by the GARNET 
Coordinating Center (U01 HG005157). Assistance with data cleaning was provided by the National 
Center for Biotechnology Information. Funding support for genotyping, which was performed at the 
Broad Institute of MIT and Harvard, was provided by the NIH Genes, Environment and Health Initiative 
[GEI] (U01 HG004424). 
 
SHARe: Funding for WHI SNP Health Association Resource (SHARe) genotyping was provided by NHLBI 
Contract N02-HL-64278. 
 
Myocardial Infarction Genetics Consortium (MIGen) 18 
DbGaP dataset reference: The datasets used for the analyses described in this manuscript were obtained 
from dbGaP at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap through dbGaP Study Accession: 
phs000294.v1.p1  Funding Source:  R01 HL087676. National Institutes of Health, Bethesda, MD, USA 
 
Wellcome Trust Case Control Consortium (WTCCC) 19 
The principal funder of this project was the Wellcome Trust.  Case collections were funded by: Arthritis 
Research Campaign, BDA Research, British Heart Foundation, British Hypertension Society, Diabetes UK, 
Glaxo-Smith Kline Research and Development, Juvenile Diabetes Research Foundation, National 
Association for Colitis and Crohn's disease, SHERT (The Scottish Hospitals Endowment Research Trust), St 
Bartholomew's and The Royal London Charitable Foundation, UK Medical Research Council, UK NHS 
R&D and the Wellcome Trust. 
 
Global Lipid Genetic Consortium (GLGC) 3,4 
Data on coronary artery disease / myocardial infarction have been contributed by Global Lipids Genetics 
Consortium investigators and have been downloaded from: 
www.sph.umich.edu/csg/abecasis/public/lipids2013/ 
 
CARDIoGRAMplusC4D Consortium 20 
CARDIoGRAMplusC4D 1000 Genomes-based GWAS is a meta-analysis of GWAS studies of mainly 
European, South Asian, and East Asian, descent imputed using the 1000 Genomes phase 1 v3 training 
set with 38 million variants. The study interrogated 9.4 million variants and involved 60,801 CAD cases 
51 
 
and 123,504 controls.  Data on coronary artery disease / myocardial infarction have been contributed by 
CARDIoGRAMplusC4D investigators and have been downloaded from www.CARDIOGRAMPLUSC4D.ORG 
 
MAGNETIC NMR GWAS 5 
External validation data from a genome-wide association study of 39 million genetic markers and 233 
human blood lipid and metabolite concentrations, including the lipid concentrations and composition of 
14 lipoprotein subclasses, quantified by automated high-throughput serum NMR metabolomics platform 
in 14 genotyped data sets derived from ten European studies for up to 24,925 individuals was provided 
by: http://www.computationalmedicine.fi/data/NMR_GWAS/ 
 
INTERVAL Bioresource 6 
External validation data from a genome-wide association study of 39 million genetic markers and 233 
human blood lipid and metabolite concentrations quantified by automated high-throughput serum NMR 
metabolomics platform in up to 40,904 participants enrolled in the INTERVL trial, a randomised trial 
assessing how often blood donors can safely give whole blood.  Data provided by the Cardiovascular 
Epidemiology Unit, University of Cambridge.   
 
Additional Data Sources: 
Data on SNP annotation, proxy search and estimates of pairwise linkage disequilibrium metrics were 
obtained using LDlink, a suite of web-based applications designed to easily and efficiently interrogate 
linkage disequilibrium in population groups. All population genotype data originates from Phase 3 
(Version 5) of the 1000 Genomes Project and variant RS numbers are indexed based on dbSNP build 142. 
Where coordinates are specified, GRCh37/hg19 is used.  LDlink was developed by Mitchell Machiela in 
collaboration with NCI's Center for Biomedical Informatics and Information Technology (CBIIT). Support 
comes from the Division of Cancer Epidemiology and Genetics Informatics Tool Challenge.1,2   
 
Data on genotyping platform specific SNP identification was obtained from NCBI dbSNP Human Build 
141:  http://www.ncbi.nlm.nih.gov/SNP/ 
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eTable 1: Included studies and genotyping platforms 
 
 
 
Study 
 
Total No. 
Participants 
 
No. Primary 
CV Events 
 
 
Follow-up 
(Years) 
 
 
Included Genetic Sub-studies 
 
 
Genotyping Platforms 
UK Biobank 367,641 18,154 7 n/a UK Biobank Axiom array  
Atherosclerosis Risk in Communities 
Study (ARIC) 15 
15,347  2,114 
 
16 phs000090 GENEVA_ARIC 
phs000557 ARIC_CARe 
Affymetrix  AFFY_6.0 
Illumina  CVDSNP55v1_A 
Cardiovascular Health Study (CHS) 16 5,583 1,614 14 phs000377 CARe Cardiovascular Health Study 
phs000226 STAMPEED: Cardiovascular Health 
Study 
Illumina  CVDSNP55v1_A 
Illumina HumanOmni1-Quad_v1-0_B 
The Framingham Heart Study (FHS):                       
 
Original Cohort 17 
Offspring Cohort 18 
 
5,209 
5,124 
 
 
428  
527 
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32 
phs000342 Framingham SHARe 
phs000282 Framingham CARe 
Affymetrix  HuGeneFocused 50K_Affy 
Affymetrix 500K Set 
(Mapping250K_Nsp and 
Mapping250K_Sty Arrays) 
Illumina  CVDSNP55v1_A 
Multi-Ethnic Study of Atherosclerosis 
(MESA) 19 
 
7,674 423  10 phs000420 MESA SHARe 
phs000283 MESA CARe 
Affymetrix  AFFY_6.0 
Illumina  CVDSNP55v1_A 
Coronary Artery Risk Development in 
Young Adults (CARDIA) 20 
3,622 21  15 phs000309 GENEVA_CARDIA 
phs000613 CARDIA_CARe 
Affymetrix  AFFY_6.0 
Illumina  CVDSNP55v1_A 
Women's Health Initiative (WHI) 21 49,234 2154  16 phs000386 WHI SHARe 
phs000315 WHI GARNET 
phs000227 PAGE WHI 
Affymetrix  AFFY_6.0 
Illumina  HumanOmni1-Quad_v1-0_B 
Illumina  Cardio-
Metabo_Chip_11395247_A 
Myocardial Infarction Genetics 
Consortium (MIGen) 7 
ATVB  
FINRISK  
HARPS 
MALMO  
MGH-PCOD 
REGICOR 
 
 
3,361 
339 
1,064 
185 
464 
629 
 
 
1,693 
167 
505 
86 
204 
312 
 
 
Case-control 
Case-control 
Case-control 
Case-control 
Case-control 
Case-control 
phs000294 STAMPEED: Myocardial Infarction 
Genetics Consortium (MIGen) 
Affymetrix  AFFY_6.0 
 
Wellcome Trust Case Control 
Consortium (WTCCC) 8 
5,002 1926 Case-control 1958 British Birth Cohort controls (1504) 
UK National Blood Service controls (1500) 
Coronary Artery Disease (CAD) cases (1998)  
Affymetrix 500K (Mapping250K_Nsp 
and Mapping250K_Sty Arrays) 
CARDIoGRAMplusC4D Consortium 184,305 60,801 Meta-
analysis of 
48 studies 
1000 Genomes-based GWAS imputed using the 1000 Genomes 
phase 1 v3 training set with 38 million 
variants. The study interrogated 9.4 
million variants. 
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eTable 2: LPL variants included in LPL score and associations with plasma triglycerides and LDL-C in 
Global Lipids Genetics Consortium 
 
 
 
SNP 
 
Effect 
Allele 
Effect 
Allele 
frequency 
 
Sample 
Size (n) 
 
TG 
(mg/dl) 
 
TG 
SE 
 
 
P 
 
LDL-C 
(mg/dl) 
 
LDL-C 
SE 
 
 
P 
rs1801177 G 0.987 304,596 -15.013 0.906 1.97E-61 -0.296 0.333 0.374 
rs268 A 0.982 290,452 -18.798 0.788 9.60E-126 -0.592 0.332 0.074 
rs301 C 0.237 305,699 -9.143 0.233 2.08E-336 0.109 0.101 0.273 
rs326 G 0.305 305,699 -14.913 0.354 3.80E-388 0.015 0.093 0.867 
rs328 G 0.098 305,699 -9.365 0.308 1.97E-203 0.402 0.142 0.005 
 
 
eTable 2 Legend: Plasma triglyceride and LDL-C effect sizes measured in mg/dl. For each variant, the exposure 
allele is the allele associated with lower triglycerides. The range of the unweighted LPL score was 1 – 10, with a 
mean of 5.2 and standard deviation of 1.5.  The range of the LPL score weighted by the association of each 
exposure allele with apoB was 6.75 -33.57, with a mean of 23.35 and standard deviation 3.11.   
 
 
 
 
 
 
 
eTable 3: Linkage disequilibrium matrix for variants included in the LPL genetic score 
 
 
LPL variant rs1801177 rs268 rs301 rs326 rs328 
rs1801177 1.0 0.0 0.005 0.004 0.001 
rs268 0.0 1.0 0.0 0.0 0.001 
rs301 0.005 0.0 1.0 0.281 0.161 
rs326 0.004 0.0 0.281 1.0 0.19 
rs328 0.001 0.001 0.161 0.19 1.0 
 
 
 
eTable 3 Legend: Values represent r2 values, a measure of linkage disequilibrium.  r2 values range from 0 to 1; with 
0 representing complete equilibrium (no evidence for linkage disequilibrium) and 1 representing complete 
disequilibrium. Variants were included in the score if they had an r2 value < 0.3 with all other variants included in 
the score using the conditional forward step-wise procedure described in the eMethods.  
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eTable 4: LDLR variants included in LDLR genetic score and their and associations with plasma 
triglycerides and LDL-C in Global Lipids Genetics Consortium 
 
 
 
SNP 
 
Effect 
Allele 
Effect 
Allele 
frequency 
 
Sample 
Size (n) 
 
TG 
(mg/dl) 
 
TG 
SE 
 
 
P 
 
LDL-C 
(mg/dl) 
 
LDL-C 
SE 
 
 
P 
rs6511720 T 0.1086 295,826 -3.1213 2.0551 0.128 -6.7657 0.1362 3.69E-538 
rs1122608 T 0.2266 262,102 -1.6781 0.6923 0.015 -2.1179 0.1075 2.02E-86 
rs688 C 0.5586 166,792 -0.2937 0.2436 0.229 -1.728 0.1184 3.04E-48 
 
 
eTable 4 Legend: Plasma triglyceride and LDL-C effect sizes measured in mg/dl. For each variant, the exposure 
allele is the allele associated with lower LDL-C.  The range of the unweighted LDLR score was 1 – 6, with a mean of 
1.8 and standard deviation of 1.2.  The range of the LDLR score weighted by the association of each exposure allele 
with apoB was 0 -18.33, with a mean of 4.04 and standard deviation 3.54.   
 
 
 
 
eTable 5: Linkage disequilibrium matrix for variants included in the LDLR genetic score 
 
LDLR variant rs1122608 rs6511720 rs688 
rs1122608 1.0 0.064 0.003 
rs6511720 0.064 1.0 0.0 
rs688 0.003 0.0 1.0 
 
 
eTable 5 Legend: Values represent r2 values, a measure of linkage disequilibrium.  r2 values range from 0 to 1; with 
0 representing complete equilibrium (no evidence for linkage disequilibrium) and 1 representing complete 
disequilibrium. Variants were included in the score if they had an r2 value < 0.3 with all other variants included in 
the score using the conditional forward step-wise procedure described in the eMethods. 
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eTable 6:  Association of LPL and LDLR scores with CHD risk per 10 mg/dl lower apoB among studies 
contributing individual participant data and summary level data  
 
 
Study sample 
sample size 
(n) 
no. CHD 
events 
genetic 
score 
 
OR (95% CI) 
     
All studies 654,783 91,129 LPL 0.771 (0.741 - 0.802) 
(IPD and summary data)   LDLR 0.773 (0.747 - 0.801) 
     
Studies with individual participant data  470,478 30,328 LPL 0.761 (0.715 - 0.809) 
(UK Biobank and dbGAP studies)   LDLR 0.767 (0.722 - 0.815) 
     
Studies with summary level data 184,305 60,801 LPL 0.780 (0.738 - 0.824) 
(CARDIoGRAMplusC4D)   LDLR 0.776 (0.744 - 0.810) 
     
 
eTable 6 Legend: OR is odds ratio for each genetic score scaled per 10 mg/dl lower apoB.   The main analysis of all 
studies involved a total of 654,783 participants, including 91,129 cases of CHD.  Analyses of studies with individual 
data involved 470,478 participants, including 30,328 cases of CHD.  Analyses of studies with summary level data 
involved 184,305 participants, including 60,801 cases of CHD. 
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eTable 7: variants associated with triglycerides or LDL-C in the Global Lipids Genetics Consortium   
position rsid annotation EA EAF TG TG SE LDL-C LDL-C SE apoB apoB SE CHD CHD SE 
1:109818530 rs646776 CELSR2:Intergenic C 0.23 -1.128 0.286 -5.281 0.109 -3.502 0.224 -0.110 0.010 
1:150958836 rs267733 ANXA9:Asp166Gly G 0.14 -0.469 0.331 -0.825 0.129 -0.204 0.102 0.001 0.012 
1:172346548 rs1011731 DNM3:Intron A 0.56 -1.302 0.234 -0.125 0.089 -0.461 0.157 -0.017 0.008 
1:183094547 rs20558 LAMC1:Leu888Pro T 0.44 0.046 0.226 -0.495 0.089 -0.377 0.216 -0.015 0.008 
1:219687432 rs2785990 LYPLAL1:Intergenic C 0.31 -1.389 0.243 -0.314 0.096 -0.284 0.144 -0.003 0.008 
1:221057646 rs2738755 HLX:Pro356Leu T 0.33 0.373 0.243 -0.495 0.092 -0.359 0.162 0.008 0.008 
1:230304988 rs10489615 GALNT2:Intron G 0.56 -3.385 0.234 -0.069 0.089 -0.696 0.176 -0.027 0.008 
1:23766233 rs1077514 ASAP3:Intron C 0.18 -1.649 0.304 -0.495 0.116 -0.452 0.241 -0.016 0.011 
1:25768937 rs10903129 TMEM57:Intron A 0.48 -0.660 0.226 -0.924 0.089 -0.474 0.089 -0.011 0.008 
1:27138393 rs12748152 PIGV:Intergenic C 0.928 -2.691 0.434 -1.023 0.168 -1.077 0.245 -0.023 0.012 
1:39797055 rs16826069 MACF1:Ile39Val A 0.79 -2.171 0.278 0.015 0.109 -0.450 0.275 -0.014 0.009 
1:55496039 rs11206510 PCSK9:Intergenic C 0.17 -0.868 0.304 -2.309 0.119 -2.122 0.209 -0.062 0.010 
1:55504650 rs2479409 PCSK9:Intergenic A 0.66 -0.174 0.234 -1.551 0.092 -1.095 0.171 -0.026 0.009 
1:55505647 rs11591147 PCSK9:Arg46Leu T 0.015 -0.425 0.955 -15.84 0.363 -8.787 0.462 -0.225 0.032 
1:55529187 rs505151 PCSK9:Gly670Glu A 0.95 -0.573 0.529 -2.968 0.205 -1.671 0.325 -0.059 0.022 
1:63118196 rs10889353 DOCK7:Intron C 0.33 -6.684 0.243 -1.485 0.092 -1.132 0.121 -0.012 0.008 
2:118835841 rs10490626 MTOR:Intergenic A 0.068 -0.955 0.469 -1.749 0.182 -1.151 0.224 -0.018 0.015 
2:165528876 rs13389219 FLG:Intergenic T 0.4 -3.212 0.243 -0.314 0.096 -0.601 0.148 -0.020 0.009 
2:169830155 rs2287623 ABCB11:Intron A 0.59 -0.694 0.234 -0.693 0.089 -0.566 0.132 -0.006 0.008 
2:202122995 rs3769823 CASP8:Lys14Arg A 0.31 -1.476 0.243 -0.043 0.096 -0.029 0.203 -0.007 0.009 
2:20396122 rs6749689 EPHA2:Intergenic C 0.57 -1.389 0.226 -0.363 0.086 -0.506 0.141 -0.013 0.008 
2:21225485 rs1801702 APOB:Arg4270Thr G 0.028 -0.556 0.686 -3.003 0.264 -1.630 0.432 -0.054 0.030 
2:21229160 rs5742904 APOB:Arg3527Gln C 0.99962 19.096 5.816 -48.84 2.244 -22.085 5.991 -0.590 0.165 
2:21233972 rs533617 APOB:His1923Arg C 0.039 -8.506 0.582 -4.289 0.224 -3.686 0.274 -0.079 0.027 
2:21238367 rs12713843 APOB:Arg1128His T 0.0044 -6.769 1.736 -7.590 0.661 -3.686 0.838 -0.119 0.061 
2:21242613 rs41288783 APOB:Pro994Leu G 0.99937 15.624 4.514 -18.48 1.749 -7.602 3.093 -0.245 0.125 
2:21252534 rs13306194 APOB:Arg532Trp A 0.0052 -8.333 1.736 -3.958 0.659 -6.038 2.418 -0.147 0.151 
2:21263900 rs1367117 APOB:Thr98Ile G 0.72 -1.996 0.252 -3.629 0.099 -2.083 0.122 -0.038 0.022 
2:21294975 rs541041 TNFSF4:Intergenic G 0.19 -1.562 0.295 -3.963 0.112 -2.339 0.161 -0.058 0.011 
2:219555262 rs1344642 STK36:Arg583Gln A 0.44 -1.302 0.226 -0.254 0.089 -0.303 0.131 -0.003 0.008 
2:227093745 rs2943641 ALDH4A1:Intergenic T 0.34 -2.864 0.243 -0.221 0.092 -0.618 0.204 -0.036 0.009 
2:234668570 rs887829 UGT1A10:Intron T 0.34 -0.625 0.243 -0.726 0.092 -0.307 0.145 -0.002 0.009 
2:27730940 rs1260326 GCKR:Leu446Pro C 0.63 -10.416 0.234 -0.759 0.092 -1.225 0.108 -0.022 0.009 
2:44028013 rs11556157 DYNC2LI1:Ile230Leu A 0.74 -0.694 0.261 -0.825 0.099 -0.316 0.168 -0.021 0.011 
2:44074431 rs4245791 ABCG8:Intron T 0.72 -1.649 0.259 -2.376 0.102 -1.881 0.201 -0.051 0.009 
2:62871225 rs11125936 TCEB3:Intergenic C 0.1 -1.389 0.373 -0.924 0.145 -0.667 0.202 -0.018 0.014 
3:12393125 rs1801282 PPARG:Pro12Ala G 0.12 -1.996 0.347 -0.109 0.135 -0.097 0.096 -0.002 0.012 
3:12628920 rs2290159 RAF1:Intron C 0.2 -0.955 0.331 -0.693 0.129 -0.461 0.168 -0.006 0.010 
3:135926622 rs645040 RFX5:Intergenic G 0.22 -1.996 0.269 -0.363 0.106 -0.663 0.178 -0.032 0.010 
3:32533010 rs7640978 CMTM6:Intron T 0.092 -0.312 0.391 -1.089 0.152 -0.583 0.288 -0.014 0.015 
3:52532118 rs13326165 STAB1:Intron A 0.19 -1.736 0.286 -0.109 0.112 -0.351 0.343 -0.017 0.011 
57 
 
position rsid annotation EA EAF TG TG SE LDL-C LDL-C SE apoB apoB SE CHD CHD SE 
3:52584787 rs2251219 PBRM1:Pro1466Pro T 0.62 0.075 0.234 -0.528 0.092 -0.430 0.242 -0.009 0.008 
3:57528503 rs9311651 DNAH12:Val32Ala G 0.17 -1.823 0.312 -0.069 0.119 -0.304 0.476 -0.026 0.013 
3:58381287 rs13315871 PXK:Intron A 0.085 -0.217 0.417 -1.254 0.162 -0.761 0.249 -0.024 0.015 
4:100045616 rs1126673 ADH4:Val374Ile C 0.28 -1.476 0.252 -0.185 0.099 -0.229 0.166 -0.003 0.009 
4:100504664 rs3816873 MTTP:Ile128Thr C 0.26 -0.295 0.262 -0.561 0.099 -0.596 0.168 -0.038 0.009 
4:103188709 rs13107325 SLC39A8:Ala391Thr T 0.051 2.951 0.521 -1.155 0.201 -0.531 0.363 -0.009 0.016 
4:3446091 rs3748034 HGFAC:Ala218Ser G 0.86 -3.038 0.365 -0.627 0.142 -0.881 0.251 -0.025 0.012 
4:3449652 rs16844401 HGFAC:Arg509His G 0.934 -2.604 0.477 -0.661 0.185 -0.761 0.351 -0.044 0.016 
4:3473139 rs6831256 DOK7:Intron A 0.56 -1.823 0.226 -0.429 0.089 -0.569 0.258 -0.024 0.008 
4:69343287 rs976002 TMPRSS11E:Tyr303Cys A 0.77 -1.302 0.278 -0.759 0.109 -0.685 0.255 -0.017 0.010 
4:88030261 rs442177 AFF1:Intron G 0.43 -2.691 0.226 -0.281 0.089 -0.442 0.122 0.012 0.008 
4:89740128 rs13133548 FAM13A:Intron G 0.52 -1.215 0.226 -0.122 0.086 -0.338 0.177 -0.021 0.011 
5:122855416 rs4530754 CSNK1G3:Intron G 0.45 0.252 0.234 -0.561 0.092 -0.486 0.171 -0.015 0.008 
5:131008194 rs26008 FNIP1:Gln620Arg C 0.92 -2.432 0.417 0.089 0.158 -0.502 0.314 -0.029 0.015 
5:131744574 rs1016988 CD101:Intergenic C 0.22 0.764 0.269 -0.663 0.106 -0.291 0.124 0.003 0.011 
5:156390297 rs6882076 TIMD4:Upstream T 0.37 -3.298 0.234 -1.287 0.089 -1.018 0.117 -0.029 0.009 
5:176520243 rs351855 FGFR4:Gly388Arg A 0.29 -0.712 0.278 -0.594 0.109 -0.369 0.138 -0.012 0.012 
5:53300662 rs4311394 ARL15:Intron A 0.73 -1.562 0.252 -0.129 0.099 -0.511 0.407 -0.028 0.012 
5:55861786 rs9686661 ASPM:Intergenic C 0.81 -3.646 0.286 -0.314 0.112 -0.802 0.185 -0.037 0.011 
5:67714246 rs4976033 IGFN1:Intergenic A 0.58 -1.562 0.226 -0.096 0.089 -0.324 0.288 -0.012 0.009 
5:74651084 rs3846662 HMGCR:Intron A 0.52 -0.331 0.234 -2.145 0.089 -1.378 0.113 -0.032 0.008 
6:116387134 rs1999930 SLC16A4:Intergenic T 0.25 0.165 0.278 -0.594 0.106 -0.601 0.143 -0.007 0.008 
6:127452935 rs2745353 RSPO3:Intron C 0.47 -1.736 0.226 -0.099 0.086 -0.583 0.159 -0.016 0.008 
6:135411228 rs9376090 VPS13D:Intergenic C 0.24 -0.259 0.269 -0.825 0.106 -0.725 0.242 -0.022 0.012 
6:135418635 rs7775698 VPS13D:Intergenic T 0.25 -0.278 0.262 -0.858 0.102 -0.737 0.296 -0.024 0.011 
6:139839423 rs643381 TXNIP:Intergenic A 0.5 -1.996 0.226 -0.198 0.089 -0.771 0.217 -0.024 0.008 
6:160543148 rs12208357 SLC22A1:Arg61Cys C 0.938 -2.778 0.469 -1.914 0.182 -1.501 0.251 -0.006 0.016 
6:160578860 rs1564348 SLC22A1:Intron T 0.85 -1.736 0.312 -1.551 0.122 -0.607 0.226 -0.038 0.014 
6:16145325 rs9370867 MYLIP:Asn342Ser G 0.53 -0.131 0.234 -1.089 0.089 -0.595 0.103 -0.014 0.008 
6:26093141 rs1800562 HFE:Cys102Tyr A 0.048 0.703 0.538 -1.452 0.208 -1.171 0.371 -0.032 0.018 
6:31262169 rs3873379 BLZF1:Intergenic T 0.68 -2.429 0.252 -0.294 0.096 -0.706 0.197 -0.017 0.010 
6:31379109 rs1051794 MICA:Glu196Lys G 0.7 -0.261 0.269 -0.693 0.102 -0.531 0.140 -0.001 0.011 
6:31440082 rs1055569 HCG26:Exon C 0.66 -0.781 0.262 -0.627 0.099 -0.375 0.151 -0.009 0.009 
6:31564821 rs2844480 F5:Intergenic C 0.8 -1.996 0.286 -0.312 0.112 -0.642 0.175 -0.009 0.011 
6:32052444 rs61995676 TNXB:Arg1064His C 0.979 -8.072 0.816 -0.759 0.314 -0.501 1.136 -0.017 0.031 
6:32261252 rs7775397 C6orf10:Glu317Ala G 0.085 -3.125 0.434 -0.561 0.168 -0.202 0.243 -0.002 0.016 
6:32586854 rs9271366 PADI4:Intergenic G 0.15 -2.083 0.33 -0.594 0.125 -0.840 0.271 -0.028 0.012 
6:32671103 rs13192471 ASTN1:Intergenic T 0.84 -1.476 0.321 -1.254 0.122 -0.653 0.218 -0.003 0.013 
6:32813279 rs1057373 TAP1:Utr3 C 0.903 -2.604 0.399 -0.168 0.152 -0.293 0.230 -0.004 0.012 
6:43758873 rs6905288 SH2D5:Intergenic G 0.41 -2.864 0.234 -0.317 0.089 -0.964 0.226 -0.039 0.011 
6:43811762 rs9472138 SH2D5:Intergenic T 0.27 -1.736 0.263 -0.267 0.102 -0.565 0.171 -0.012 0.009 
6:52453220 rs2239619 HSPG2:Intergenic C 0.38 -0.085 0.234 -0.594 0.092 -0.367 0.128 -0.005 0.009 
7:116358044 rs38855 MET:Intron G 0.46 -1.215 0.226 -0.116 0.089 -0.256 0.112 -0.006 0.008 
7:130433384 rs4731702 SNX27:Intergenic T 0.46 -2.344 0.234 -0.218 0.089 -0.519 0.134 -0.020 0.010 
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position rsid annotation EA EAF TG TG SE LDL-C LDL-C SE apoB apoB SE CHD CHD SE 
7:17284577 rs4410790 NCSTN:Intergenic T 0.41 -1.302 0.234 -0.182 0.089 -0.606 0.166 -0.021 0.011 
7:21607352 rs12670798 DNAH11:Intron T 0.75 -1.128 0.269 -1.089 0.106 -1.177 0.133 -0.028 0.008 
7:25991826 rs4722551 HMCN1:Intergenic T 0.84 2.257 0.321 -1.321 0.125 -0.455 0.188 -0.008 0.012 
7:44444122 rs11550029 NUDCD3:Arg235Cys G 0.83 -1.128 0.304 -0.661 0.116 -0.745 0.213 -0.017 0.011 
7:73012042 rs35332062 MLXIPL:Ala358Val A 0.12 -10.416 0.356 0.462 0.135 -0.765 0.207 -0.022 0.013 
8:10683929 rs11776767 PINX1:Intron G 0.63 -1.913 0.243 0.195 0.092 -0.139 0.081 0.008 0.010 
8:116599199 rs2293889 TRPS1:Intron G 0.62 -0.356 0.234 -0.495 0.089 -0.189 0.453 -0.005 0.009 
8:116648565 rs2737229 TRPS1:Intron C 0.34 -1.128 0.243 -0.726 0.096 -0.318 0.081 -0.005 0.009 
8:11702375 rs3947 CTSB:Utr3 G 0.77 -2.083 0.295 0.053 0.112 -0.172 0.161 -0.004 0.011 
8:126490972 rs2954029 AMPD1:Intergenic T 0.45 -6.944 0.226 -1.584 0.089 -1.812 0.141 -0.049 0.008 
8:145058986 rs11136343 PARP10:Leu395Pro A 0.62 -0.321 0.234 -0.957 0.092 -0.567 0.111 -0.002 0.009 
8:18272881 rs1495741 PGLYRP4:Intergenic A 0.75 -3.038 0.262 -0.726 0.102 -0.668 0.204 -0.028 0.011 
8:55421614 rs10102164 CRP:Intergenic G 0.8 -1.302 0.278 -1.023 0.109 -0.799 0.16 -0.024 0.010 
8:59388565 rs2081687 IGSF9:Intergenic C 0.66 -1.649 0.234 -0.924 0.092 -0.535 0.094 -0.007 0.009 
8:9183596 rs4841132 NECAP2:Intergenic A 0.09 3.038 0.382 -1.881 0.149 -0.641 0.161 -0.011 0.015 
9:107664301 rs1883025 ABCA1:Intron T 0.26 -1.911 0.252 -0.792 0.099 -0.876 0.197 -0.028 0.011 
9:136155000 rs635634 IL6R:Intergenic C 0.81 0.955 0.295 -2.541 0.116 -1.579 0.182 -0.061 0.015 
9:139368953 rs3812594 SEC16A:Arg1039Cys A 0.24 0.564 0.269 -0.594 0.102 -0.306 0.167 -0.011 0.012 
9:16887366 rs3927680 OR6P1:Intergenic A 0.52 -1.562 0.234 -0.429 0.089 -0.670 0.146 -0.021 0.008 
9:19376255 rs67710536 RPS6:Utr3 A 0.89 -0.347 0.382 -0.924 0.149 -1.112 0.377 -0.030 0.015 
9:2640759 rs3780181 VLDLR:Intron G 0.074 0.521 0.425 -1.221 0.165 -0.862 0.341 -0.008 0.016 
10:113940329 rs2792751 GPAM:Ile43Val C 0.73 1.736 0.252 -0.924 0.099 -0.507 0.246 -0.012 0.009 
10:124610027 rs1891110 FAM24B:Pro2Leu G 0.45 -0.269 0.226 -0.693 0.086 -0.162 0.061 -0.003 0.008 
10:64927823 rs1935 JMJD1C:Glu2299Asp C 0.52 2.517 0.226 -0.594 0.089 -0.141 0.209 -0.012 0.008 
10:94839642 rs2068888 C1orf106:Intergenic A 0.47 -2.778 0.226 -0.528 0.089 -0.649 0.116 -0.018 0.008 
11:116639104 rs10790162 BUD13:Intron G 0.92 -22.568 0.408 -1.089 0.162 -3.059 0.252 -0.060 0.015 
11:116662407 rs3135506 APOA5:Ser19Trp G 0.941 -18.532 0.424 -1.573 0.187 -2.62 0.234 -0.059 0.017 
11:116701353 rs76353203 APOC3:Arg19Stp T 0.00045 -105.896 5.642 -4.291 2.178 -2.889 5.347 -0.174 0.230 
11:116701354 rs138326449 APOC3:Essential_Splice_Site A 0.0018 -68.870 4.485 -4.290 1.518 -7.482 2.020 -0.188 0.149 
11:116896155 rs10892063 SIK3:Intron C 0.58 -5.034 0.261 -0.208 0.099 -0.542 0.115 -0.013 0.009 
11:126160826 rs8177399 TIRAP:Arg13Trp C 0.982 -1.911 0.842 -2.013 0.327 -1.697 0.591 -0.076 0.029 
11:126243952 rs11220462 ST3GAL4:Intron G 0.86 -0.495 0.391 -1.419 0.149 -1.023 0.201 -0.018 0.014 
11:18645843 rs11024739 SPTY2D1:Intron C 0.32 -0.764 0.261 -0.825 0.099 -0.498 0.137 -0.014 0.008 
11:47270255 rs2167079 ACP2:Arg29Gln T 0.35 -1.736 0.243 -0.033 0.096 -0.336 0.116 -0.003 0.009 
11:61569830 rs174546 FADS1:Utr3 T 0.31 4.514 0.252 -1.749 0.096 -0.772 0.152 -0.023 0.009 
11:64031241 rs35169799 PLCB3:Ser778Leu C 0.941 -3.298 0.477 -0.191 0.185 -0.719 0.299 -0.032 0.016 
11:65391317 rs12801636 PCNXL3:Intron A 0.23 -1.562 0.269 0.251 0.102 -0.308 0.165 -0.045 0.011 
11:66297363 rs3816492 BBS1:Leu472Leu T 0.23 -0.339 0.278 -0.594 0.109 -0.479 0.197 -0.008 0.011 
12:107174646 rs10861661 RIC8B:Intron A 0.77 -1.649 0.278 -0.028 0.106 -0.481 0.161 -0.012 0.009 
12:121416650 rs1169288 HNF1A:Ile27Leu A 0.67 -0.202 0.252 -1.221 0.096 -0.474 0.168 -0.042 0.009 
12:124427306 rs11057401 CCDC92:Ser70Cys A 0.3 -2.432 0.243 -0.195 0.096 -0.521 0.142 -0.042 0.009 
12:125307053 rs11057830 SCARB1:Intron G 0.85 -1.302 0.329 -0.759 0.125 -0.977 0.284 -0.063 0.011 
12:21331549 rs4149056 SLCO1B1:Val174Ala T 0.86 -2.517 0.330 0.271 0.129 -0.140 0.198 0.030 0.011 
12:57809456 rs1106766 CFH:Intergenic T 0.21 -2.604 0.278 -0.429 0.106 -0.601 0.157 -0.036 0.009 
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13:32953388 rs4942486 BRCA2:Intron C 0.52 -0.738 0.226 -0.726 0.089 -0.658 0.153 -0.018 0.008 
14:24883887 rs8017377 NYNRIN:Ala978Thr G 0.58 -0.321 0.234 -0.759 0.089 -0.433 0.164 -0.004 0.008 
14:64235556 rs7157785 NPR1:Intergenic G 0.82 -1.996 0.321 -0.363 0.125 -0.470 0.199 -0.002 0.012 
14:71096344 rs9646133 FLAD1:Intergenic T 0.33 -0.037 0.243 -0.627 0.092 -0.484 0.166 -0.015 0.009 
14:74250126 rs13379043 C14orf43:Intron C 0.31 -0.746 0.252 -0.594 0.099 -0.363 0.182 -0.020 0.009 
14:94844947 rs28929474 SERPINA1:Glu366Lys C 0.985 -1.823 0.955 -2.673 0.363 -1.765 0.342 0.125 0.033 
15:40751555 rs3803357 BAHD1:Gln298Lys A 0.54 -1.476 0.226 0.014 0.089 -0.171 0.116 -0.002 0.009 
15:43820717 rs55707100 MAP1A:Pro2349Leu C 0.976 -11.284 0.738 -0.244 0.284 -2.314 0.441 0.002 0.027 
15:58678512 rs10468017 SNX27:Intergenic C 0.73 -2.951 0.252 -0.109 0.099 -0.894 0.146 -0.014 0.009 
15:58723675 rs1800588 SNX27:Intergenic C 0.76 -4.082 0.259 -0.032 0.102 -1.296 0.155 -0.015 0.012 
16:15129970 rs7200543 PDXDC1:Leu736Leu A 0.69 -2.083 0.252 0.011 0.099 -0.241 0.192 -0.011 0.011 
16:56989590 rs247616 OR10K2:Intergenic T 0.31 -3.125 0.243 -1.056 0.096 -0.911 0.124 -0.042 0.009 
16:57015091 rs5880 CETP:Ala390Pro G 0.952 -3.385 0.582 -0.561 0.228 -1.386 0.304 -0.036 0.021 
16:72108093 rs2000999 HPR:Intron G 0.8 -1.823 0.304 -2.079 0.116 -1.387 0.178 -0.042 0.012 
16:81534790 rs2925979 CMIP:Intron C 0.7 -2.517 0.243 -0.099 0.096 -0.111 0.341 0.000 0.019 
17:17409560 rs7946 PEMT:Val212Met T 0.67 -1.389 0.252 -0.238 0.096 -0.304 0.161 -0.012 0.009 
17:26694861 rs704 VTN:Thr400Met G 0.51 0.547 0.226 -0.693 0.086 -0.196 0.128 -0.005 0.008 
17:29629326 rs11080150 NF1:Intron G 0.33 -0.217 0.243 -0.627 0.092 -0.368 0.101 -0.009 0.008 
17:41926126 rs72836561 CD300LG:Arg82Cys C 0.972 -11.284 0.686 0.891 0.264 -1.246 0.357 -0.061 0.024 
17:41931375 rs12453522 CD300LG:Thr194Ala A 0.82 -1.823 0.295 0.017 0.116 0.326 0.249 -0.011 0.011 
17:45732774 rs11871606 KPNB1:Intron A 0.5 1.389 0.226 -0.891 0.086 -0.526 0.141 -0.018 0.008 
17:64210580 rs1801689 APOH:Cys325Gly A 0.973 4.081 0.694 -3.303 0.271 -1.481 0.543 -0.059 0.024 
17:67081278 rs77542162 ABCA6:Cys1359Arg A 0.985 3.212 1.128 -6.271 0.429 -2.868 0.571 -0.033 0.035 
17:7091650 rs314253 CRB1:Intergenic C 0.35 -0.486 0.234 -0.659 0.092 -0.331 0.197 -0.011 0.009 
17:73782191 rs2125345 UNK:Intron C 0.31 -0.955 0.252 -0.792 0.099 -0.595 0.138 -0.024 0.009 
17:76395430 rs2292642 PGS1:Gly172Gly T 0.61 -1.736 0.226 0.429 0.089 -0.177 0.137 -0.001 0.009 
19:11275139 rs7188 KANK2:Utr3 A 0.68 -0.955 0.243 -1.584 0.092 -1.468 0.146 -0.032 0.009 
19:19379549 rs58542926 TM6SF2:Glu167Lys T 0.074 -10.416 0.434 -3.304 0.165 -2.645 0.233 -0.045 0.016 
19:45316588 rs28399654 BCAM:Val196Ile A 0.027 6.336 0.712 -8.910 0.277 -4.694 0.372 -0.113 0.024 
19:45395266 rs157580 TOMM40:Intron G 0.37 -4.081 0.234 -2.376 0.089 -2.081 0.122 -0.039 0.009 
19:45410002 rs769449 APOE:Intron G 0.89 -5.729 0.365 -6.27 0.139 -3.637 0.170 -0.090 0.013 
19:45412079 rs7412 APOE:Arg176Cys T 0.075 10.416 0.564 -17.82 0.211 -7.636 0.212 -0.163 0.018 
19:46181392 rs1800437 GIPR:Glu354Gln C 0.2 0.477 0.278 -0.627 0.109 -0.306 0.161 -0.008 0.011 
19:49206417 rs492602 FUT2:Ala69Ala A 0.55 -1.562 0.243 -0.924 0.092 -0.581 0.173 -0.017 0.008 
19:50000009 rs2280401 RPS11:Intron A 0.15 -1.736 0.312 -0.528 0.119 -0.579 0.156 -0.015 0.011 
20:12962718 rs364585 DBT:Intergenic A 0.36 1.042 0.243 -0.627 0.092 -0.504 0.192 -0.013 0.009 
20:17596155 rs1132274 RRBP1:Arg891Leu C 0.83 -0.295 0.304 -0.627 0.116 -0.544 0.252 -0.041 0.011 
20:34116282 rs7261862 C20orf173:Lys194Glu C 0.18 -1.128 0.295 -0.792 0.116 -0.699 0.353 -0.012 0.011 
20:39154095 rs6016373 SLC27A3:Intergenic G 0.39 -0.746 0.234 -0.792 0.089 -0.807 0.161 -0.021 0.008 
20:39672618 rs6029526 TOP1:Intron T 0.49 -1.128 0.234 -1.155 0.089 -0.685 0.144 -0.022 0.008 
20:43042364 rs1800961 HNF4A:Thr117Ile T 0.031 0.373 0.651 -1.782 0.251 -0.839 0.325 -0.019 0.024 
20:44576502 rs7679 PCIF1:Utr3 T 0.83 -4.604 0.304 -0.363 0.116 0.477 0.164 0.018 0.016 
20:62695931 rs6062343 TCEA2:Intron A 0.43 -1.562 0.234 -0.462 0.089 -0.482 0.159 -0.025 0.009 
22:35660875 rs1053593 HMGXB4:Gly165Val T 0.61 -0.582 0.252 -0.528 0.096 -0.244 0.151 -0.004 0.009 
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22:38569006 rs738322 PLA2G6:Intron G 0.49 -1.736 0.226 -0.053 0.089 -0.214 0.121 -0.002 0.008 
22:39100128 rs5757251 NPR1:Intergenic G 0.61 -1.389 0.252 -0.142 0.099 -0.063 0.137 0.014 0.009 
22:41170063 rs2076674 SLC25A17:Intron T 0.65 0.174 0.243 -0.594 0.092 -0.384 0.178 -0.014 0.009 
22:44324727 rs738409 PNPLA3:Ile149Met G 0.23 -1.562 0.269 -0.594 0.102 -0.706 0.229 -0.028 0.014 
22:45996298 rs13268 FBLN1:His695Arg G 0.021 -0.056 0.781 -1.749 0.301 -0.763 0.355 -0.011 0.027 
22:46627780 rs1042311 PPARA:Ala268Val C 0.9951 -5.902 1.649 -3.960 0.627 -2.417 0.790 -0.055 0.056 
 
eTable 7 Legend: EA is effect allele, EAF is effect allele frequency; TG is triglycerides, SE is standard error.   
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eTable 8: Additional multivariable Mendelian randomization analyses for the association between 
changes in triglycerides, LDL-C, apoB and the risk of coronary heart disease    
 
A.    183 variants associated with either TG or LDL-C (p < 5.0x10-8) not including LPL or LDLR variants 
 
Model Included variables ORCHD (95% CI) p value 
    
1 LDL-C 0.845 (0.832 - 0.858)  2.75E-75 
    
2 Triglycerides 0.826 (0.792 - 0.861)  6.48E-16 
    
3 apoB 0.771 (0.759 - 0.781)  1.26E-163 
    
4 LDL-C 0.860 (0.847 - 0.873)  8.86E-64 
 Triglycerides 0.877 (0.849 - 0.906)  1.79E-12 
    
5 apoB 0.762 (0.724 - 0.802)  6.11E-19 
 LDL-C 1.014 (0.971 - 1.059)  0.183 
 Triglycerides 1.003 (0.955 - 1.054)  0.177 
    
 
 
 
B.    51 variants associated with TG at p < 5.0x10-8); but not LDL-C (p > 0.001) 
 
Model Included variables ORCHD (95% CI) p value 
    
1 LDL-C 0.626 (0.543 - 0.721)  5.35E-05 
    
2 Triglycerides 0.823 (0.782 - 0.865)  4.38E-10 
    
3 apoB 0.765 (0.730 - 0.802)  1.60E-17 
    
4 LDL-C 0.879 (0.703 - 1.101)  0.322 
 Triglycerides 0.842 (0.789 - 0.899)  1.42E-05 
    
5 apoB 0.778 (0.711 - 0.851)  1.79E-05 
 LDL-C 0.971 (0.776 - 1.213)  0.795 
 Triglycerides 0.989 (0.892 - 1.097)  0.841 
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C.    59 variants associated with LDL-C at p < 5.0x10-8; but not TG (p > 0.001) 
 
Model Included variables ORCHD (95% CI) p value 
    
1 LDL-C 0.859 (0.844 - 0.876)  1.56E-41 
    
2 Triglycerides 1.017 (0.545 - 1.897)  0.285 
    
3 apoB 0.774 (0.754 - 0.794)  3.45E-51 
    
4 LDL-C 0.861 (0.845 - 0.878)  2.65E-40 
 Triglycerides 0.827 (0.671 - 1.021)  0.142 
    
5 apoB 0.770 (0.689 - 0.861)  3.85E-04 
 LDL-C 1.003 (0.919 - 1.095)  0.944 
 Triglycerides 0.999 (0.769 - 1.298)  0.992 
    
 
 
eTable 8 Legend: Data are from genetic variants associated with either triglycerides, LDL-C or both at genome-
wide significance as reported by the updated Global Lipids Genetics Consortium and listed in eTable 6.  Effect sizes 
for the associated risk of coronary heart disease are per 10 mg/dl decrease in apoB; 10 mg/dl decrease in LDL-C, or 
a 50 mg/dl decrease in triglycerides (because dividing triglyceride concentration by 5 estimates the cholesterol 
content carried by triglyceride-rich apoB-containing lipoproteins as estimated by the Friedewald formula).  The 
results are derived from a multivariable meta-regression analysis where the dependent variable is the effect 
estimate for risk of coronary heart disease, and the independent variables are the effect estimates for the 
associated changes in plasma triglycerides, LDL-C and apoB, for each variant.  The analysis was weighted by the 
inverse squared standard error of the associated risk of CHD for each variant; and forced to pass through the 
origin.   
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 eFigure 1: Study design and analyses 
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eFigure 2: Plot of LPL variants included in LPL score 
 
 
 
 
 
 
 
 
 
 
 
 
 
eFigure 3: Plot of LDLR variants included in LDLR score 
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Figure 4: Associations of the LPL and LDLR scores with plasma lipid levels and risk of coronary heart 
disease for the same change in plasma concentration of apoB-containing lipoproteins stratified by the 
other score 
 
 
 
 
 
 
 
 
 
 
 
eFigure 4 Legend:  Data are from analyses of 470,478 participants with individual participant data including 30,328 
cases of CHD.  Changes in lipid levels were obtained from up 72,411 participants with individual participant data 
for whom one or more lipid measurements were available.  Boxes represent point estimates of effect. Lines 
represent 95% error bars.     
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A.  Unadjusted Associations 
eFigure 5: 2x2 Factorial Mendelian randomization analysis evaluating the separate and combined effects 
of the LPL and LDLR scores on plasma lipids, lipoproteins, and risk of coronary heart disease  
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3 Legend:  Data are from analyses of 470,478 participants with individual participant data including 30,328 
cases of CHD.  Changes in lipid levels were obtained from up 72,411 participants with individual participant data 
for whom one or more lipid measurements were available.  Boxes represent point estimates of effect. Lines 
represent 95% confidence intervals. 
     
B. Associations with CHD adjusted per 10 mg/dl lower apoB 
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